Effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	B-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
RWLeu-4	B-cell_line
.	O

The	O
effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	B-cell_line
chromosome-positive	I-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
RWLeu-4	B-cell_line
,	O
were	O
investigated	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000-3000	O
sites/cell	O
,	O
and	O
half-maximal	O
binding	O
occurring	O
at	O
0.21-0.33	O
nM	O
.	O

Treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
induced	O
24R-hydroxylase	B-protein
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues	O
.	O

Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O

Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage/monocyte	B-cell_type
type	I-cell_type
cells	I-cell_type
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic	O
.	O

Progressive	O
expression	O
of	O
cell	B-protein
surface	I-protein
maturation-specific	I-protein
antigens	I-protein
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O

c-myc	B-RNA
RNA	I-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	B-cell_line
cells	I-cell_line
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O

Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr-abl	B-protein
oncogene	I-protein
product	I-protein
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O

Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
50	NULL
,	NULL
3087-3094	NULL
,	NULL
May	NULL
15	NULL
,	NULL
1990	NULL
]	NULL
Effects	NULL
of	NULL
1a	NULL
Â«	NULL
,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
on	NULL
the	NULL
Human	NULL
Chronic	NULL
Myelogenous	NULL
Leukemia	NULL
Cell	NULL
Line	NULL
RWLeu-4	NULL
'	NULL
Stephen	NULL
R.	NULL
Lasky	NULL
,	NULL
``	NULL
William	NULL
Bell	NULL
,	NULL
Richard	NULL
D.	NULL
Huhn	NULL
,	NULL
Marshall	NULL
R.	NULL
Posner	NULL
,	NULL
Michael	NULL
Wiemann	NULL
,	NULL
Paul	NULL
Calabresi	NULL
,	NULL
and	NULL
Charles	NULL
Eil	NULL
Department	NULL
of	NULL
Medicine	NULL
[	NULL
R.	NULL
D.	NULL
H.	NULL
,	NULL
P.	NULL
C.	NULL
]	NULL
,	NULL
Divisions	NULL
of	NULL
Endocrinology	NULL
[	NULL
S.	NULL
R.	NULL
L.	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
C.	NULL
E.	NULL
]	NULL
and	NULL
Hematology/Oncology	NULL
[	NULL
M.	NULL
R.	NULL
P.	NULL
,	NULL
M.	NULL
W.	NULL
]	NULL
,	NULL
Roger	NULL
Williams	NULL
General	NULL
Hospital	NULL
and	NULL
Brown	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Providence	NULL
,	NULL
Rhode	NULL
Island	NULL
02908	NULL
ABSTRACT	NULL
The	NULL
effects	NULL
of	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
(	NULL
VD	NULL
,	NULL
)	NULL
on	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
macromolecular	NULL
synthesis	NULL
in	NULL
the	NULL
new	NULL
Philadelphia	NULL
chromosome-positive	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
RWLeu-4	NULL
,	NULL
were	NULL
investigated	NULL
.	NULL

Binding	NULL
of	NULL
PHJVD	NULL
;	NULL
,	NULL
was	NULL
saturable	NULL
,	NULL
with	NULL
approximately	NULL
2000-3000	NULL
sites/cell	NULL
,	NULL
and	NULL
half-maximal	NULL
binding	NULL
occurring	NULL
at	NULL
0.21-0.33	NULL
nm	NULL
.	NULL

Treatment	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
with	NULL
VD	NULL
;	NULL
induced	NULL
24	NULL
R-hydroxylase	NULL
activity	NULL
,	NULL
a	NULL
marker	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
responsiveness	NULL
in	NULL
many	NULL
tissues	NULL
.	NULL

Exposure	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
to	NULL
VD	NULL
;	NULL
also	NULL
inhibited	NULL
proliferation	NULL
and	NULL
DNA	NULL
synthesis	NULL
with	NULL
a	NULL
50	NULL
%	NULL
effective	NULL
dose	NULL
of	NULL
3.5-10	NULL
nm	NULL
within	NULL
72	NULL
h	NULL
;	NULL
in	NULL
addition	NULL
,	NULL
protein	NULL
and	NULL
RNA	NULL
synthesis	NULL
were	NULL
inhibited	NULL
by	NULL
VD	NULL
;	NULL
treatment	NULL
.	NULL

Exposure	NULL
of	NULL
RWLeu-4	NULL
cells	NULL
to	NULL
5	NULL
nv	NULL
VD	NULL
;	NULL
for	NULL
72	NULL
h	NULL
caused	NULL
50	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
to	NULL
differentiate	NULL
into	NULL
macrophage/monocyte	NULL
type	NULL
cells	NULL
as	NULL
judged	NULL
by	NULL
nitroblue	NULL
tetrazolium	NULL
staining	NULL
and	NULL
adherence	NULL
to	NULL
plastic	NULL
.	NULL

Progressive	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
maturation-specific	NULL
antigens	NULL
of	NULL
the	NULL
monocyte/macrophage	NULL
lineage	NULL
was	NULL
induced	NULL
by	NULL
treatment	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
with	NULL
VD	NULL
;	NULL
for	NULL
24	NULL
to	NULL
72	NULL
h	NULL
at	NULL
doses	NULL
that	NULL
inhibited	NULL
cellular	NULL
proliferation	NULL
.	NULL

c-myc	NULL
RNA	NULL
,	NULL
which	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
RWLeu-4	NULL
cells	NULL
,	NULL
increased	NULL
after	NULL
0.5	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
50	NULL
nv	NULL
VD	NULL
;	NULL
and	NULL
then	NULL
rapidly	NULL
decreased	NULL
to	NULL
barely	NULL
detectable	NULL
levels	NULL
after	NULL
4	NULL
h	NULL
of	NULL
treatment	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
in	NULL
vitro	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
associated	NULL
with	NULL
the	NULL
p210	NULL
``	NULL
**	NULL
``	NULL
oncogene	NULL
product	NULL
was	NULL
decreased	NULL
approximately	NULL
50	NULL
%	NULL
by	NULL
VD	NULL
;	NULL
treatment	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
functional	NULL
receptor-effector	NULL
system	NULL
for	NULL
VD	NULL
;	NULL
and	NULL
multiple	NULL
biological	NULL
responses	NULL
to	NULL
the	NULL
hormone	NULL
,	NULL
these	NULL
cells	NULL
provide	NULL
a	NULL
unique	NULL
model	NULL
system	NULL
with	NULL
which	NULL
to	NULL
probe	NULL
the	NULL
specific	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

INTRODUCTION	NULL
VD	NULL
;	NULL
is	NULL
a	NULL
sterol	NULL
hormone	NULL
with	NULL
well	NULL
known	NULL
actions	NULL
in	NULL
calcium	NULL
and	NULL
phosphate	NULL
homeostasis	NULL
.	NULL

Most	NULL
,	NULL
if	NULL
not	NULL
all	NULL
,	NULL
of	NULL
its	NULL
actions	NULL
are	NULL
mediated	NULL
in	NULL
a	NULL
fashion	NULL
prototypic	NULL
of	NULL
steroid	NULL
hormones	NULL
via	NULL
the	NULL
binding	NULL
and	NULL
activation	NULL
of	NULL
high	NULL
affinity	NULL
nuclear	NULL
receptors	NULL
.	NULL

The	NULL
activated	NULL
receptors	NULL
then	NULL
modulate	NULL
gene	NULL
expression	NULL
by	NULL
binding	NULL
to	NULL
regulatory	NULL
regions	NULL
of	NULL
one	NULL
or	NULL
more	NULL
genes	NULL
(	NULL
1	NULL
)	NULL
.	NULL

In	NULL
classical	NULL
target	NULL
tissues	NULL
,	NULL
VD	NULL
;	NULL
enhances	NULL
the	NULL
expression	NULL
of	NULL
calcium-binding	NULL
protein	NULL
,	NULL
alkaline	NULL
phosphatase	NULL
,	NULL
and	NULL
the	NULL
24-hydroxylase	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

Extremely	NULL
sensitive	NULL
radioligand	NULL
receptor	NULL
binding	NULL
assays	NULL
have	NULL
now	NULL
shown	NULL
that	NULL
VD	NULL
;	NULL
receptors	NULL
are	NULL
present	NULL
not	NULL
only	NULL
in	NULL
the	NULL
classical	NULL
target	NULL
tissues	NULL
such	NULL
as	NULL
bone	NULL
,	NULL
intestinal	NULL
mucosa	NULL
,	NULL
and	NULL
Received	NULL
9/13/88	NULL
;	NULL
revised	NULL
1/31/90	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Rhode	NULL
Island	NULL
Foundation	NULL
(	NULL
to	NULL
S.	NULL
R.	NULL
L.	NULL
)	NULL
and	NULL
the	NULL
NIH	NULL
(	NULL
P30-CA13943	NULL
to	NULL
the	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Roger	NULL
Williams	NULL
General	NULL
Hospital	NULL
,	NULL
RO1-CA50558	NULL
to	NULL
S.	NULL
R.	NULL
L.	NULL
and	NULL
RO1-CA38687	NULL
to	NULL
M.	NULL
R.	NULL
P.	NULL
)	NULL
.	NULL

R.	NULL
D.	NULL
H.	NULL
was	NULL
a	NULL
fellow	NULL
of	NULL
the	NULL
Pharmaceutical	NULL
Manufacturers	NULL
'	NULL
Association	NULL
Foundation	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Roger	NULL
Williams	NULL
General	NULL
Hospital	NULL
,	NULL
825	NULL
Chalkstone	NULL
Ave.	NULL
,	NULL
Providence	NULL
,	NULL
RI	NULL
02908	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
VD	NULL
;	NULL
,	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
;	NULL
D	NULL
;	NULL
,	NULL
vitamin	NULL
D	NULL
;	NULL
;	NULL
25-D	NULL
;	NULL
,	NULL
,	NULL
25-hydroxyvitamin	NULL
D	NULL
;	NULL
;	NULL
24R,25-D	NULL
,	NULL
,	NULL
24R,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
;	NULL
CML	NULL
,	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
;	NULL
24-hydroxylase	NULL
,	NULL
25-hydroxyvitamin	NULL
D	NULL
,	NULL
24	NULL
R-hydroxylase	NULL
;	NULL
FCS	NULL
,	NULL
fetal	NULL
calf	NULL
serum	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
10	NULL
mm	NULL
potassium	NULL
phosphate-146	NULL
mm	NULL
NaCl	NULL
,	NULL
pH	NULL
7.2	NULL
)	NULL
;	NULL
SSPE	NULL
,	NULL
NaCl-sodium	NULL
phosphate	NULL
;	NULL
TPA	NULL
,	NULL
-	NULL
12-O-tetradecanoylphorbol-l3-acetate	NULL
;	NULL
-	NULL
TCA	NULL
,	NULL
-	NULL
trichloroacetic	NULL
-	NULL
acid	NULL
;	NULL
TEDKzso+	NULL
,	NULL
10	NULL
mm	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
-1	NULL
mm	NULL
EDTA-10	NULL
mm	NULL
dithiothreitol-2	NULL
mm	NULL
phenyImethylsulfonyi	NULL
fluoride-50	NULL
g/ml	NULL
aprotinin-50	NULL
Â«	NULL
g/ml	NULL
leupeptin-300	NULL
mm	NULL
KCl	NULL
;	NULL
SDS	NULL
,	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
;	NULL
KB	NULL
,	NULL
kinase	NULL
buffer	NULL
;	NULL
NBT	NULL
,	NULL
nitroblue	NULL
tetrazolium	NULL
;	NULL
EDs	NULL
,	NULL
50	NULL
%	NULL
effective	NULL
dose	NULL
;	NULL
PK	NULL
,	NULL
,	NULL
protein	NULL
kinase	NULL
C.	NULL
kidney	NULL
,	NULL
where	NULL
they	NULL
function	NULL
to	NULL
regulate	NULL
calcium	NULL
and	NULL
phosphate	NULL
mobilization	NULL
,	NULL
absorption	NULL
,	NULL
and	NULL
resorption	NULL
,	NULL
but	NULL
are	NULL
also	NULL
found	NULL
in	NULL
the	NULL
skin	NULL
,	NULL
endocrine	NULL
glands	NULL
,	NULL
brain	NULL
,	NULL
thymus	NULL
,	NULL
bone	NULL
marrow	NULL
,	NULL
and	NULL
activated	NULL
or	NULL
transformed	NULL
lymphopoietic	NULL
cells	NULL
,	NULL
among	NULL
other	NULL
tissues	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
high	NULL
affinity	NULL
VD	NULL
;	NULL
receptors	NULL
in	NULL
so	NULL
many	NULL
cell	NULL
types	NULL
suggests	NULL
that	NULL
the	NULL
biological	NULL
functions	NULL
of	NULL
this	NULL
hormone	NULL
may	NULL
go	NULL
well	NULL
beyond	NULL
calcium	NULL
and	NULL
phosphate	NULL
homeo-stasis	NULL
;	NULL
indeed	NULL
,	NULL
it	NULL
has	NULL
been	NULL
proposed	NULL
that	NULL
VD	NULL
;	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
,	NULL
cell	NULL
growth	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
differentiation	NULL
in	NULL
many	NULL
diverse	NULL
systems	NULL
(	NULL
1	NULL
,	NULL
5-12	NULL
)	NULL
.	NULL

Because	NULL
VD	NULL
;	NULL
is	NULL
known	NULL
to	NULL
affect	NULL
the	NULL
differentiation	NULL
of	NULL
certain	NULL
leukemia	NULL
cell	NULL
lines	NULL
(	NULL
4-12	NULL
)	NULL
we	NULL
were	NULL
interested	NULL
in	NULL
the	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
cells	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
CML	NULL
.	NULL

In	NULL
approximately	NULL
90	NULL
%	NULL
of	NULL
CML	NULL
cases	NULL
,	NULL
the	NULL
leukemic	NULL
cells	NULL
bear	NULL
a	NULL
cytogenetic	NULL
abnormality	NULL
known	NULL
as	NULL
the	NULL
Philadelphia	NULL
chromosome	NULL
(	NULL
Ph	NULL
'	NULL
)	NULL
,	NULL
a	NULL
shortened	NULL
chromosome	NULL
22	NULL
resulting	NULL
from	NULL
a	NULL
reciprocal	NULL
translocation	NULL
of	NULL
the	NULL
long	NULL
arms	NULL
of	NULL
chromosomes	NULL
9	NULL
and	NULL
22	NULL
[	NULL
t	NULL
(	NULL
9	NULL
;	NULL
22	NULL
)	NULL
q34	NULL
;	NULL
q1	NULL
1	NULL
]	NULL
(	NULL
13	NULL
)	NULL
.	NULL

This	NULL
translocation	NULL
results	NULL
in	NULL
the	NULL
fusion	NULL
of	NULL
the	NULL
ber	NULL
and	NULL
abl	NULL
protooncogenes	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
210kDa	NULL
BCR-ABL	NULL
fusion	NULL
protein	NULL
with	NULL
constitutive	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
which	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
etiology	NULL
of	NULL
CML	NULL
(	NULL
14	NULL
)	NULL
.	NULL

It	NULL
is	NULL
of	NULL
note	NULL
that	NULL
agents	NULL
which	NULL
induce	NULL
in	NULL
vitro	NULL
differentiation	NULL
of	NULL
CML	NULL
cells	NULL
[	NULL
e.g	NULL
.	NULL

,	NULL
1-8-p-arabinofuranosylcytosine	NULL
(	NULL
15	NULL
)	NULL
;	NULL
a	NULL
Â«	NULL
-inter-feron	NULL
(	NULL
16	NULL
)	NULL
]	NULL
can	NULL
lead	NULL
to	NULL
remissions	NULL
in	NULL
this	NULL
disease	NULL
when	NULL
administered	NULL
therapeutically	NULL
.	NULL

As	NULL
part	NULL
of	NULL
our	NULL
investigations	NULL
of	NULL
CML	NULL
,	NULL
Wiemann	NULL
et	NULL
al	NULL
.	NULL

(	NULL
17	NULL
)	NULL
have	NULL
established	NULL
the	NULL
permanent	NULL
cell	NULL
line	NULL
,	NULL
RWLeu-4	NULL
,	NULL
from	NULL
a	NULL
patient	NULL
in	NULL
the	NULL
blast	NULL
phase	NULL
of	NULL
CML	NULL
.	NULL

These	NULL
cells	NULL
are	NULL
Ph	NULL
'	NULL
positive	NULL
and	NULL
express	NULL
an	NULL
aberrant	NULL
p210	NULL
``	NULL
*	NULL
``	NULL
fusion	NULL
protein	NULL
with	NULL
constitutive	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
(	NULL
18	NULL
)	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
for	NULL
the	NULL
characteristics	NULL
of	NULL
RWLeu-4	NULL
)	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
RWLeu-4	NULL
cells	NULL
possess	NULL
high	NULL
affinity	NULL
receptors	NULL
for	NULL
VD	NULL
;	NULL
and	NULL
that	NULL
treatment	NULL
of	NULL
RW	NULL
cells	NULL
with	NULL
this	NULL
natural	NULL
seco-sterol	NULL
hormone	NULL
causes	NULL
them	NULL
to	NULL
cease	NULL
prolifer-ating	NULL
,	NULL
inhibits	NULL
macromolecular	NULL
synthesis	NULL
,	NULL
and	NULL
induces	NULL
them	NULL
to	NULL
differentiate	NULL
into	NULL
cells	NULL
with	NULL
the	NULL
characteristics	NULL
of	NULL
mature	NULL
mono-cytes	NULL
or	NULL
macrophages	NULL
.	NULL

We	NULL
also	NULL
show	NULL
that	NULL
the	NULL
level	NULL
of	NULL
c-myc	NULL
mRNA	NULL
within	NULL
these	NULL
cells	NULL
is	NULL
rapidly	NULL
altered	NULL
by	NULL
VD	NULL
,	NULL
treatment	NULL
and	NULL
that	NULL
the	NULL
level	NULL
of	NULL
p210	NULL
``	NULL
``	NULL
~**-associated	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
is	NULL
decreased	NULL
after	NULL
exposure	NULL
to	NULL
VD	NULL
;	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
.	NULL

VD	NULL
;	NULL
,	NULL
24R,25-D	NULL
;	NULL
,	NULL
and	NULL
25-D	NULL
;	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
M.	NULL
R.	NULL
Uskokovic	NULL
,	NULL
Hoffman-LaRoche	NULL
Inc.	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
VD	NULL
;	NULL
were	NULL
prepared	NULL
in	NULL
absolute	NULL
ethanol	NULL
,	NULL
sparged	NULL
with	NULL
nitrogen	NULL
gas	NULL
,	NULL
and	NULL
protected	NULL
from	NULL
direct	NULL
light	NULL
.	NULL

TPA	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
,	NULL
dissolved	NULL
in	NULL
acetone	NULL
,	NULL
and	NULL
protected	NULL
from	NULL
direct	NULL
light	NULL
.	NULL

Agarose	NULL
,	NULL
guanidinium	NULL
thiocyanate	NULL
,	NULL
cesium	NULL
chloride	NULL
,	NULL
formamide	NULL
,	NULL
and	NULL
restriction	NULL
enzymes	NULL
were	NULL
from	NULL
International	NULL
Biotechnologies	NULL
,	NULL
Inc.	NULL
Nytran	NULL
nylon	NULL
transfer	NULL
membranes	NULL
were	NULL
purchased	NULL
from	NULL
Schleicher	NULL
and	NULL
Schuell	NULL
.	NULL

High	NULL
performance	NULL
liquid	NULL
chromatography	NULL
grade	NULL
methanol	NULL
,	NULL
chloroform	NULL
,	NULL
isopropyl	NULL
alcohol	NULL
,	NULL
and	NULL
hexane	NULL
were	NULL
purchased	NULL
from	NULL
Baker	NULL
Chemical	NULL
Co.	NULL
All	NULL
other	NULL
chemicals	NULL
were	NULL
of	NULL
the	NULL
highest	NULL
commercially	NULL
available	NULL
purity	NULL
.	NULL

[	NULL
(	NULL
26,27	NULL
)	NULL
Â°H	NULL
}	NULL
-25-hydroxyvitamin	NULL
D	NULL
;	NULL
,	NULL
[	NULL
(	NULL
26,27	NULL
)	NULL
Â°H	NULL
}	NULL
-1	NULL
@	NULL
Â«	NULL
,25-dihydroxy-vitamin	NULL
D	NULL
;	NULL
,	NULL
(	NULL
PHJVD	NULL
Â»	NULL
:	NULL
)	NULL
,	NULL
[	NULL
y-P	NULL
]	NULL
JATP	NULL
,	NULL
and	NULL
{	NULL
Â«	NULL
-	NULL
``	NULL
P	NULL
]	NULL
dCTP	NULL
were	NULL
purchased	NULL
3087	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

1a,25-DIHYDROXYVITAMIN	NULL
D	NULL
;	NULL
,	NULL
EFFECTS	NULL
ON	NULL
CML	NULL
CELLS	NULL
from	NULL
New	NULL
England	NULL
Nuclear	NULL
.	NULL

[	NULL
5HJuridine	NULL
,	NULL
and	NULL
Universolyv	NULL
liquid	NULL
scintillation	NULL
cocktail	NULL
were	NULL
purchased	NULL
from	NULL
ICN	NULL
.	NULL

Cells	NULL
and	NULL
Cell	NULL
Culture	NULL
.	NULL

The	NULL
human	NULL
leukemic	NULL
cell	NULL
line	NULL
RWLeu-4	NULL
was	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
Gibco	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
at	NULL
37Â°C	NULL
.	NULL

Cells	NULL
were	NULL
inoculated	NULL
at	NULL
1	NULL
or	NULL
2	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
and	NULL
grown	NULL
exponentially	NULL
for	NULL
3-4	NULL
days	NULL
.	NULL

Viability	NULL
of	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
.	NULL

Following	NULL
treatment	NULL
with	NULL
VD	NULL
;	NULL
the	NULL
morphological	NULL
characteristics	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
determined	NULL
by	NULL
examination	NULL
of	NULL
Wright-Giemsa-stained	NULL
cells	NULL
and	NULL
photomicrographs	NULL
made	NULL
using	NULL
a	NULL
Reichert	NULL
photomicroscope	NULL
with	NULL
Kodak	NULL
Pan-ASA	NULL
50	NULL
film	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
VD	NULL
;	NULL
to	NULL
undergo	NULL
oxidative	NULL
metabolism	NULL
,	NULL
which	NULL
is	NULL
a	NULL
characteristic	NULL
of	NULL
differentiation	NULL
into	NULL
mature	NULL
monocyte/	NULL
macrophage-like	NULL
cells	NULL
,	NULL
was	NULL
determined	NULL
by	NULL
NBT	NULL
reduction	NULL
using	NULL
a	NULL
kit	NULL
purchased	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Company	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Assays	NULL
for	NULL
myeloperoxidase	NULL
,	NULL
naphthol	NULL
AS-D	NULL
chloroacetate	NULL
esterase	NULL
(	NULL
specific	NULL
ester-ase	NULL
)	NULL
,	NULL
and	NULL
a-naphthol	NULL
acetate	NULL
esterase	NULL
(	NULL
nonspecific	NULL
esterase	NULL
)	NULL
activities	NULL
were	NULL
also	NULL
performed	NULL
according	NULL
to	NULL
instructions	NULL
included	NULL
in	NULL
the	NULL
kits	NULL
from	NULL
Sigma	NULL
.	NULL

Immunofluorescent	NULL
Detection	NULL
of	NULL
Cell	NULL
Surface	NULL
Antigens	NULL
.	NULL

Indirect	NULL
immunofluorescent	NULL
detection	NULL
of	NULL
cell	NULL
surface	NULL
antigens	NULL
was	NULL
performed	NULL
,	NULL
with	NULL
slight	NULL
modifications	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cultures	NULL
with	NULL
2	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
were	NULL
treated	NULL
with	NULL
diluent	NULL
alone	NULL
or	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
during	NULL
the	NULL
culture	NULL
period	NULL
of	NULL
72	NULL
h	NULL
,	NULL
the	NULL
final	NULL
cell	NULL
density	NULL
was	NULL
determined	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
PBS	NULL
at	NULL
1	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
.	NULL

Then	NULL
10Â°	NULL
cells/sample	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
and	NULL
the	NULL
cells	NULL
resuspended	NULL
in	NULL
100	NULL
Ll	NULL
of	NULL
a	NULL
solution	NULL
containing	NULL
murine	NULL
monoclonal	NULL
antibodies	NULL
reactive	NULL
with	NULL
cell	NULL
surface	NULL
differentiation	NULL
markers	NULL
,	NULL
appropriately	NULL
diluted	NULL
in	NULL
Puck	NULL
's	NULL
Saline	NULL
G	NULL
with	NULL
2.5	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
FCS	NULL
.	NULL

The	NULL
cell/antibody	NULL
suspension	NULL
was	NULL
then	NULL
incubated	NULL
at	NULL
4Â°C	NULL
for	NULL
30	NULL
min	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
100	NULL
Ll	NULL
of	NULL
Puck	NULL
's	NULL
Saline	NULL
G	NULL
with	NULL
2.5	NULL
%	NULL
FCS	NULL
containing	NULL
diluted	NULL
fluorescein-conjugated	NULL
goat	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
;	NULL
anti-mouse	NULL
im-munoglobulins	NULL
(	NULL
Tago	NULL
,	NULL
Inc.	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
sample	NULL
was	NULL
then	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4Â°C	NULL
and	NULL
washed	NULL
once	NULL
with	NULL
cold	NULL
PBS	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
suspended	NULL
in	NULL
0.25	NULL
ml	NULL
of	NULL
cold	NULL
PBS	NULL
supplemented	NULL
with	NULL
0.1	NULL
%	NULL
EDTA	NULL
and	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
ice	NULL
cold	NULL
1	NULL
%	NULL
formaldehyde	NULL
in	NULL
PBS/	NULL
EDTA	NULL
was	NULL
added	NULL
to	NULL
fix	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stored	NULL
for	NULL
up	NULL
to	NULL
96	NULL
h	NULL
at	NULL
4Â°C	NULL
until	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
an	NULL
EPICS	NULL
C	NULL
cell	NULL
sorter	NULL
(	NULL
Coulter	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

The	NULL
significance	NULL
of	NULL
the	NULL
changes	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
antigens	NULL
was	NULL
analyzed	NULL
using	NULL
the	NULL
Wilcoxon	NULL
rank	NULL
sums	NULL
test	NULL
on	NULL
data	NULL
from	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

VD	NULL
,	NULL
Receptor	NULL
Assay	NULL
.	NULL

Retention	NULL
of	NULL
[	NULL
26,27Â°HJVD	NULL
;	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
RWLeu-4	NULL
cells	NULL
was	NULL
quantitated	NULL
as	NULL
described	NULL
by	NULL
Eil	NULL
and	NULL
Marx	NULL
(	NULL
20	NULL
)	NULL
and	NULL
binding	NULL
parameters	NULL
were	NULL
calculated	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Scatchard	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
JVD	NULL
;	NULL
to	NULL
cytosolic	NULL
receptors	NULL
was	NULL
assayed	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
technique	NULL
described	NULL
by	NULL
Liberman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
22	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
log	NULL
phase	NULL
RWLeu-4	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
cold	NULL
PBS	NULL
and	NULL
resuspended	NULL
at	NULL
3	NULL
to	NULL
6	NULL
million	NULL
cells/ml	NULL
in	NULL
ice	NULL
cold	NULL
TEDK	NULL
;	NULL
Â»	NULL
,	NULL
.	NULL

All	NULL
subsequent	NULL
operations	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
disrupted	NULL
by	NULL
sonication	NULL
using	NULL
ten	NULL
5-s	NULL
pulses	NULL
of	NULL
a	NULL
Branson	NULL
microprobe	NULL
set	NULL
at	NULL
level	NULL
6	NULL
.	NULL

The	NULL
cell	NULL
debris	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
1	NULL
h	NULL
in	NULL
a	NULL
50Ti	NULL
rotor	NULL
.	NULL

Supernatant	NULL
(	NULL
0.2	NULL
ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
2-fold	NULL
serial	NULL
dilutions	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
-VD	NULL
:	NULL
in	NULL
siliconized	NULL
microcentrifuge	NULL
tubes	NULL
yielding	NULL
final	NULL
concentrations	NULL
of	NULL
2-0.015	NULL
nm	NULL
and	NULL
incubated	NULL
overnight	NULL
at	NULL
4Â°C	NULL
.	NULL

Then	NULL
0.4	NULL
ml	NULL
of	NULL
a	NULL
50	NULL
%	NULL
slurry	NULL
of	NULL
hydroxyapatite	NULL
in	NULL
TEDK	NULL
:	NULL
Â»	NULL
(	NULL
TEDK	NULL
Â»	NULL
.	NULL

without	NULL
protease	NULL
inhibitors	NULL
)	NULL
was	NULL
added	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
2	NULL
h.	NULL
The	NULL
hydroxyapatite	NULL
was	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
TEDK	NULL
;	NULL
,	NULL
,	NULL
containing	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
absolute	NULL
ethanol	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
radioactive	NULL
material	NULL
remaining	NULL
in	NULL
the	NULL
final	NULL
clarified	NULL
ethanol	NULL
supernatant	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Total	NULL
counts	NULL
were	NULL
determined	NULL
by	NULL
suspending	NULL
an	NULL
aliquot	NULL
of	NULL
each	NULL
dilution	NULL
of	NULL
[	NULL
PHJVD	NULL
;	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
ethanol	NULL
and	NULL
counting	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
determined	NULL
by	NULL
isotope	NULL
dilution	NULL
with	NULL
1	NULL
um	NULL
unlabeled	NULL
VD	NULL
;	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
cell	NULL
extract	NULL
,	NULL
and	NULL
nonspecific	NULL
counts	NULL
in	NULL
the	NULL
final	NULL
ethanol	NULL
wash	NULL
were	NULL
subtracted	NULL
to	NULL
give	NULL
specific	NULL
VD	NULL
;	NULL
binding	NULL
.	NULL

25-Hydroxyvitamin	NULL
D	NULL
,	NULL
24R-Hydroxylase	NULL
Assay	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
24	NULL
R-hydroxylase	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
by	NULL
Gamblin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
exponentially	NULL
growing	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
resuspended	NULL
at	NULL
a	NULL
density	NULL
of	NULL
10	NULL
%	NULL
/ml	NULL
in	NULL
serum-free	NULL
media	NULL
.	NULL

24R-Hydroxylase	NULL
was	NULL
induced	NULL
by	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
for	NULL
16	NULL
to	NULL
24	NULL
h	NULL
after	NULL
which	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
excess	NULL
VD	NULL
;	NULL
,	NULL
was	NULL
washed	NULL
out	NULL
,	NULL
and	NULL
100	NULL
pmol	NULL
[	NULL
26,27Â°H	NULL
]	NULL
25-D	NULL
;	NULL
were	NULL
added	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37Â°C	NULL
,	NULL
internal	NULL
standards	NULL
were	NULL
added	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
extracted	NULL
with	NULL
chloroform/methanol	NULL
.	NULL

The	NULL
organic	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
extract	NULL
was	NULL
dried	NULL
under	NULL
a	NULL
stream	NULL
of	NULL
nitrogen	NULL
and	NULL
dissolved	NULL
in	NULL
hexane/	NULL
isopropyl	NULL
alcohol	NULL
(	NULL
92:8	NULL
)	NULL
and	NULL
the	NULL
metabolites	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
were	NULL
separated	NULL
by	NULL
high	NULL
performance	NULL
liquid	NULL
chromatography	NULL
over	NULL
a	NULL
silica	NULL
column	NULL
with	NULL
a	NULL
mobile	NULL
phase	NULL
containing	NULL
8	NULL
%	NULL
isopropyl	NULL
alcohol	NULL
in	NULL
hexane	NULL
.	NULL

Labeled	NULL
metabolites	NULL
were	NULL
identified	NULL
by	NULL
coelution	NULL
with	NULL
internal	NULL
standards	NULL
and	NULL
the	NULL
fractions	NULL
containing	NULL
labeled	NULL
metabolites	NULL
were	NULL
quantitated	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
Cell	NULL
Proliferation	NULL
.	NULL

Triplicate	NULL
cultures	NULL
of	NULL
1	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
were	NULL
treated	NULL
in	NULL
24-well	NULL
culture	NULL
plates	NULL
with	NULL
10-fold	NULL
serial	NULL
dilutions	NULL
of	NULL
VD	NULL
;	NULL
from	NULL
107	NULL
``	NULL
to	NULL
10~	NULL
'	NULL
m	NULL
,	NULL
or	NULL
equivalent	NULL
concentrations	NULL
of	NULL
diluent	NULL
alone	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
1	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
plus	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
for	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
and	NULL
96	NULL
h.	NULL
At	NULL
the	NULL
end	NULL
of	NULL
treatment	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
chilled	NULL
and	NULL
scraped	NULL
,	NULL
and	NULL
viable	NULL
cells	NULL
were	NULL
counted	NULL
in	NULL
a	NULL
hemocytometer	NULL
.	NULL

At	NULL
least	NULL
200	NULL
cells	NULL
were	NULL
counted	NULL
from	NULL
each	NULL
culture	NULL
well	NULL
.	NULL

Viability	NULL
was	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
in	NULL
all	NULL
cultures	NULL
throughout	NULL
this	NULL
time	NULL
period	NULL
.	NULL

Effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
Cellular	NULL
DNA	NULL
,	NULL
RNA	NULL
,	NULL
and	NULL
Protein	NULL
Synthesis	NULL
.	NULL

One	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
were	NULL
treated	NULL
in	NULL
triplicate	NULL
with	NULL
2-fold	NULL
serial	NULL
dilutions	NULL
of	NULL
VD	NULL
,	NULL
from	NULL
5	NULL
x	NULL
107	NULL
``	NULL
to	NULL
1	NULL
x	NULL
10~	NULL
'	NULL
m	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
Ll	NULL
of	NULL
RPMI	NULL
1640	NULL
plus	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Control	NULL
wells	NULL
received	NULL
diluent	NULL
alone	NULL
.	NULL

Separate	NULL
96-well	NULL
microtiter	NULL
plates	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
and	NULL
96	NULL
h	NULL
before	NULL
addition	NULL
of	NULL
0.5	NULL
LCi/well	NULL
of	NULL
[	NULL
methyl-	NULL
'	NULL
H	NULL
}	NULL
thymidine	NULL
,	NULL
[	NULL
5-HJuridine	NULL
,	NULL
or	NULL
Tran	NULL
{	NULL
[	NULL
*SJlabel	NULL
.	NULL

After	NULL
a	NULL
4-h	NULL
pulse	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
onto	NULL
glass	NULL
fiber	NULL
filters	NULL
using	NULL
an	NULL
automatic	NULL
cell	NULL
harvester	NULL
(	NULL
Whitaker/Biosystems	NULL
)	NULL
.	NULL

In	NULL
experiments	NULL
to	NULL
measure	NULL
the	NULL
rate	NULL
of	NULL
DNA	NULL
or	NULL
RNA	NULL
synthesis	NULL
,	NULL
filters	NULL
were	NULL
dried	NULL
and	NULL
the	NULL
total	NULL
label	NULL
incorporated	NULL
into	NULL
macromolecular	NULL
fractions	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

In	NULL
experiments	NULL
to	NULL
measure	NULL
the	NULL
rate	NULL
of	NULL
protein	NULL
synthesis	NULL
,	NULL
after	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
onto	NULL
filter	NULL
paper	NULL
disks	NULL
,	NULL
the	NULL
filters	NULL
were	NULL
immersed	NULL
in	NULL
cold	NULL
10	NULL
%	NULL
TCA	NULL
for	NULL
5	NULL
min	NULL
followed	NULL
by	NULL
immersion	NULL
in	NULL
hot	NULL
(	NULL
90Â°C	NULL
)	NULL
5	NULL
%	NULL
TCA	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
filters	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
in	NULL
cold	NULL
5	NULL
%	NULL
TCA	NULL
and	NULL
once	NULL
in	NULL
ethanol	NULL
before	NULL
drying	NULL
and	NULL
counting	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
Total	NULL
Cellular	NULL
RNA	NULL
.	NULL

RW	NULL
Leu-4	NULL
cells	NULL
,	NULL
100	NULL
ml	NULL
inoculated	NULL
at	NULL
2	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
in	NULL
Falcon	NULL
T-200	NULL
culture	NULL
flasks	NULL
,	NULL
were	NULL
treated	NULL
for	NULL
0.5	NULL
,	NULL
2	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
treatment	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
cold	NULL
PBS	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
guanidinium	NULL
thiocyanate	NULL
procedure	NULL
developed	NULL
by	NULL
Chirgwin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
25	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
washed	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
28	NULL
ml	NULL
of	NULL
4.5	NULL
m	NULL
guanidinium	NULL
isothiocyanate-0.1	NULL
m	NULL
2-mercaptoethanol-5	NULL
mm	NULL
sodium	NULL
citrate	NULL
(	NULL
pH	NULL
7	NULL
)	NULL
,	NULL
0.5	NULL
%	NULL
Sarkosyl	NULL
and	NULL
vortexed	NULL
to	NULL
shear	NULL
the	NULL
DNA	NULL
.	NULL

The	NULL
cell	NULL
lysate	NULL
was	NULL
layered	NULL
over	NULL
a	NULL
12.5-ml	NULL
pad	NULL
of	NULL
5.7	NULL
m	NULL
CsCl-0.1	NULL
m	NULL
EDTA	NULL
and	NULL
centrifuged	NULL
for	NULL
16	NULL
to	NULL
24	NULL
h	NULL
at	NULL
24,000	NULL
rpm	NULL
in	NULL
a	NULL
Beckman	NULL
SW	NULL
28	NULL
rotor	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
then	NULL
removed	NULL
by	NULL
aspiration	NULL
,	NULL
the	NULL
tubes	NULL
were	NULL
drained	NULL
by	NULL
inversion	NULL
,	NULL
the	NULL
pellet	NULL
was	NULL
washed	NULL
first	NULL
with	NULL
70	NULL
%	NULL
ethanol	NULL
,	NULL
then	NULL
washed	NULL
with	NULL
absolute	NULL
ethanol	NULL
,	NULL
and	NULL
dried	NULL
in	NULL
a	NULL
vacuum	NULL
.	NULL

The	NULL
dried	NULL
RNA	NULL
pellet	NULL
was	NULL
then	NULL
resuspended	NULL
in	NULL
water	NULL
and	NULL
extracted	NULL
once	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
phenol	NULL
:	NULL
chloroform	NULL
:	NULL
isoamyl	NULL
alcohol	NULL
(	NULL
10:10:0.2	NULL
)	NULL
and	NULL
ethanol	NULL
precipitated	NULL
overnight	NULL
at	NULL
-20Â°C	NULL
.	NULL

The	NULL
final	NULL
RNA	NULL
peliet	NULL
was	NULL
resuspended	NULL
in	NULL
water	NULL
and	NULL
the	NULL
concentration	NULL
of	NULL
RNA	NULL
determined	NULL
by	NULL
absorbance	NULL
at	NULL
260	NULL
nm	NULL
.	NULL

RNA	NULL
Blot	NULL
Analysis	NULL
.	NULL

Total	NULL
RNA	NULL
(	NULL
20	NULL
amg	NULL
)	NULL
was	NULL
glyoxylated	NULL
,	NULL
separated	NULL
on	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
Nytran	NULL
membranes	NULL
essentially	NULL
as	NULL
described	NULL
by	NULL
Maniatis	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
.	NULL

Membranes	NULL
were	NULL
baked	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
80Â°C	NULL
in	NULL
a	NULL
vacuum	NULL
oven	NULL
,	NULL
prehybridized	NULL
with	NULL
5	NULL
x	NULL
SSPE	NULL
(	NULL
1	NULL
x	NULL
SSPE	NULL
is	NULL
8.5	NULL
mm	NULL
sodium	NULL
phosphate-149	NULL
mm	NULL
NaCl-1	NULL
mm	NULL
EDTA	NULL
)	NULL
,	NULL
10	NULL
%	NULL
Denhardt	NULL
's	NULL
solution	NULL
(	NULL
1	NULL
x	NULL
Denhardt	NULL
's	NULL
solution	NULL
is	NULL
0.2	NULL
g/liter	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
polyvinyl	NULL
pyrrolidone	NULL
,	NULL
and	NULL
Ficoll	NULL
)	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
and	NULL
100	NULL
ug/ml	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
for	NULL
90	NULL
min	NULL
at	NULL
42Â°C	NULL
,	NULL
and	NULL
then	NULL
hybridized	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
containing	NULL
2	NULL
x	NULL
10Â°	NULL
cpm/ml	NULL
of	NULL
[	NULL
Â«	NULL
-*P	NULL
]	NULL
dCMP-labeled	NULL
complementary	NULL
DNA	NULL
probes	NULL
for	NULL
>	NULL
16	NULL
h.	NULL
The	NULL
filters	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
four	NULL
changes	NULL
of	NULL
0.1	NULL
x	NULL
SSPE-0.1	NULL
%	NULL
SDS	NULL
at	NULL
55Â°C	NULL
over	NULL
2	NULL
h.	NULL
Autoradiography	NULL
was	NULL
for	NULL
1-3	NULL
days	NULL
at	NULL
-80Â°C	NULL
using	NULL
Lanex	NULL
intensifying	NULL
screens	NULL
.	NULL

Isolation	NULL
and	NULL
Labeling	NULL
of	NULL
v-myc	NULL
and	NULL
#	NULL
-Actin	NULL
Complementary	NULL
DNA	NULL
Probes	NULL
.	NULL

Cultures	NULL
of	NULL
plasmid	NULL
pMyc3pst	NULL
(	NULL
ATCC	NULL
41308	NULL
)	NULL
,	NULL
donated	NULL
to	NULL
the	NULL
ATCC	NULL
by	NULL
B.	NULL
Venstrom	NULL
,	NULL
or	NULL
plasmid	NULL
pActin	NULL
in	NULL
Escherichia	NULL
coli	NULL
HB101	NULL
were	NULL
grown	NULL
overnight	NULL
in	NULL
LB	NULL
media	NULL
supplemented	NULL
with	NULL
ampicillin	NULL
or	NULL
3088	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

1a,25-DIHYDROXYVITAMIN	NULL
D	NULL
;	NULL
EFFECTS	NULL
ON	NULL
CML	NULL
CELLS	NULL
tetracycline	NULL
.	NULL

Plasmid	NULL
DNA	NULL
was	NULL
isolated	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
alkaline	NULL
lysis/polyethylene	NULL
glycol	NULL
precipitation	NULL
procedures	NULL
of	NULL
Guo	NULL
and	NULL
Wu	NULL
(	NULL
27	NULL
)	NULL
and	NULL
Sadhu	NULL
and	NULL
Gedamu	NULL
(	NULL
28	NULL
)	NULL
.	NULL

[	NULL
a-P	NULL
]	NULL
dCTP-labeled	NULL
DNA	NULL
with	NULL
specific	NULL
activities	NULL
of	NULL
approximately	NULL
10Â°	NULL
dpm/ug	NULL
were	NULL
synthesized	NULL
using	NULL
the	NULL
random	NULL
priming	NULL
technique	NULL
of	NULL
Feinberg	NULL
and	NULL
Vogelstein	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
Vitro	NULL
p210	NULL
``	NULL
**	NULL
``	NULL
Tyrosine	NULL
Kinase	NULL
Activity	NULL
.	NULL

In	NULL
vitro	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
by	NULL
Huhn	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
exponentially	NULL
growing	NULL
RWLeu-4	NULL
cells	NULL
were	NULL
cultured	NULL
overnight	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
.	NULL

Aliquots	NULL
of	NULL
10Â°	NULL
cells	NULL
were	NULL
lysed	NULL
with	NULL
10	NULL
mm	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
-50	NULL
mm	NULL
NaCl-30	NULL
mM	NULL
sodium	NULL
pyrophosphate-50	NULL
mm	NULL
NaF-5	NULL
mm	NULL
EDTA-100	NULL
mm	NULL
sodium	NULL
o-vanadate	NULL
;	NULL
0.1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin-0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
buffer	NULL
and	NULL
the	NULL
lysates	NULL
were	NULL
precleared	NULL
of	NULL
nonspecific	NULL
proteins	NULL
by	NULL
reaction	NULL
with	NULL
nonimmune	NULL
rabbit	NULL
serum	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
.	NULL

The	NULL
precleared	NULL
lysates	NULL
were	NULL
reacted	NULL
with	NULL
rabbit	NULL
anti-abl	NULL
peptide	NULL
4	NULL
antiserum	NULL
or	NULL
nonimmune	NULL
rabbit	NULL
serum	NULL
as	NULL
a	NULL
control	NULL
.	NULL

The	NULL
immune	NULL
complexes	NULL
were	NULL
adsorbed	NULL
onto	NULL
25	NULL
ul	NULL
protein	NULL
A-Sepharose	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
the	NULL
previous	NULL
buffer	NULL
and	NULL
twice	NULL
with	NULL
KB	NULL
,	NULL
50	NULL
mm	NULL
4-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1-piper-azineethanesulfonic	NULL
acid	NULL
,	NULL
pH	NULL
7.5-0.1	NULL
mm	NULL
EDTA-0.015	NULL
%	NULL
Brij-35	NULL
.	NULL

Twenty	NULL
Â«	NULL
l	NULL
KB	NULL
,	NULL
5	NULL
Ll	NULL
50	NULL
mm	NULL
MgCl	NULL
;	NULL
,	NULL
and	NULL
5	NULL
l	NULL
(	NULL
40	NULL
mg/ml	NULL
)	NULL
angiotensin	NULL
II	NULL
were	NULL
added	NULL
as	NULL
substrate	NULL
to	NULL
the	NULL
washed	NULL
immune	NULL
complexes	NULL
;	NULL
phosphorylation	NULL
reactions	NULL
were	NULL
initiated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
5	NULL
Ll	NULL
of	NULL
1	NULL
mm	NULL
[	NULL
Â«	NULL
-	NULL
``	NULL
``	NULL
P	NULL
]	NULL
-ATP	NULL
in	NULL
KB	NULL
(	NULL
specific	NULL
activity	NULL
,	NULL
2	NULL
mCi/ml	NULL
)	NULL
.	NULL

Reactions	NULL
were	NULL
conducted	NULL
for	NULL
10	NULL
min	NULL
at	NULL
30Â°C	NULL
with	NULL
intermittent	NULL
mixing	NULL
and	NULL
quenched	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
120	NULL
ul	NULL
of	NULL
10	NULL
%	NULL
phosphoric	NULL
acid	NULL
.	NULL

Eighty	NULL
ul	NULL
of	NULL
the	NULL
supernatants	NULL
were	NULL
spotted	NULL
onto	NULL
2-cm	NULL
>	NULL
pieces	NULL
of	NULL
Whatman	NULL
p81	NULL
anion	NULL
exchange	NULL
paper	NULL
,	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
6	NULL
%	NULL
acetic	NULL
acid	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
acetone	NULL
,	NULL
and	NULL
allowed	NULL
to	NULL
air	NULL
dry	NULL
.	NULL

Adsorbed	NULL
radioactivity	NULL
was	NULL
measured	NULL
by	NULL
Cerenkov	NULL
counting	NULL
.	NULL

RESULTS	NULL
Characteristics	NULL
of	NULL
the	NULL
RWLeu-4	NULL
Cell	NULL
Line	NULL
.	NULL

Table	NULL
1	NULL
summarizes	NULL
the	NULL
characteristics	NULL
of	NULL
the	NULL
RW	NULL
Leu-4	NULL
cell	NULL
line	NULL
as	NULL
determined	NULL
by	NULL
Wiemann	NULL
et	NULL
a/	NULL
.	NULL

(	NULL
17	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
have	NULL
a	NULL
doubling	NULL
time	NULL
of	NULL
approximately	NULL
25-26	NULL
h	NULL
and	NULL
a	NULL
saturation	NULL
density	NULL
of	NULL
1.4	NULL
x	NULL
10Â°	NULL
cells/ml	NULL
,	NULL
they	NULL
are	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
independent	NULL
,	NULL
and	NULL
they	NULL
do	NULL
not	NULL
secrete	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
.	NULL

Karyotype	NULL
analysis	NULL
indicates	NULL
that	NULL
they	NULL
are	NULL
Ph	NULL
'	NULL
positive	NULL
and	NULL
analysis	NULL
of	NULL
phosphotyrosine-containing	NULL
proteins	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
indicates	NULL
that	NULL
they	NULL
express	NULL
the	NULL
p210Â°	NULL
``	NULL
*	NULL
``	NULL
tyrosine	NULL
kinase	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigens	NULL
is	NULL
undetectable	NULL
in	NULL
these	NULL
cells	NULL
RWLeu-4	NULL
will	NULL
form	NULL
tumors	NULL
in	NULL
athymic	NULL
mice	NULL
using	NULL
the	NULL
fibrin	NULL
clot	NULL
technique	NULL
developed	NULL
by	NULL
Lozzio	NULL
et	NULL
al	NULL
.	NULL

(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
are	NULL
NBT	NULL
negative	NULL
but	NULL
express	NULL
myeloperoxidase	NULL
,	NULL
naphthol	NULL
AS-D	NULL
chloroacetate	NULL
(	NULL
spe-cific	NULL
)	NULL
esterase	NULL
,	NULL
and	NULL
a-naphthol	NULL
acetate	NULL
(	NULL
non-specific	NULL
)	NULL
esterase	NULL
activities	NULL
constitutively	NULL
,	NULL
indicating	NULL
that	NULL
they	NULL
are	NULL
of	NULL
the	NULL
myeloid	NULL
lineage	NULL
.	NULL

Binding	NULL
of	NULL
VD	NULL
,	NULL
High	NULL
Affinity	NULL
Receptors	NULL
.	NULL

Since	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
activities	NULL
thus	NULL
far	NULL
attributed	NULL
to	NULL
VD	NULL
;	NULL
require	NULL
the	NULL
interaction	NULL
between	NULL
the	NULL
hormone	NULL
and	NULL
its	NULL
receptor	NULL
,	NULL
we	NULL
examined	NULL
RWLeu-4	NULL
cells	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
high	NULL
affinity	NULL
nuclear	NULL
VD	NULL
;	NULL
receptor	NULL
.	NULL

Table	NULL
1	NULL
Characteristics	NULL
of	NULL
the	NULL
RWLeu-4	NULL
cell	NULL
line	NULL
Nonspecific	NULL
esterase	NULL
represents	NULL
a~naphthol	NULL
acetate	NULL
esterase	NULL
activity	NULL
,	NULL
while	NULL
specific	NULL
esterase	NULL
indicates	NULL
naphthol	NULL
AS-D	NULL
chloroacetate	NULL
esterase	NULL
activity	NULL
.	NULL

CSF	NULL
,	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
;	NULL
EBNA	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
;	NULL
PAS	NULL
,	NULL
p-aminosalicylic	NULL
acid	NULL
.	NULL

25-26	NULL
h	NULL
1.4	NULL
million/ml	NULL
39	NULL
%	NULL
Doubling	NULL
time	NULL
Saturation	NULL
density	NULL
Cloning	NULL
efficiency	NULL
CSF	NULL
dependency	NULL
Tumorigenicity	NULL
EBNA	NULL
PAS	NULL
reactivity	NULL
Myeloperoxidase	NULL
Specific	NULL
esterase	NULL
Nonspecific	NULL
esterase	NULL
NBT	NULL
reduction	NULL
1	NULL
++	NULL
++	NULL
l	NULL
+	NULL
These	NULL
experiments	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
indicate	NULL
that	NULL
these	NULL
cells	NULL
contain	NULL
a	NULL
single	NULL
class	NULL
of	NULL
receptors	NULL
for	NULL
VD	NULL
;	NULL
present	NULL
at	NULL
approximately	NULL
3000	NULL
copies	NULL
with	NULL
an	NULL
equilibrium	NULL
dissociation	NULL
constant	NULL
(	NULL
K	NULL
,	NULL
)	NULL
of	NULL
0.33	NULL
nm	NULL
.	NULL

Because	NULL
nuclear	NULL
uptake	NULL
studies	NULL
reflect	NULL
the	NULL
measurement	NULL
of	NULL
several	NULL
complex	NULL
binding	NULL
parameters	NULL
(	NULL
binding	NULL
to	NULL
the	NULL
hormone	NULL
,	NULL
binding	NULL
to	NULL
DNA	NULL
,	NULL
and	NULL
retention	NULL
in	NULL
the	NULL
nucleus	NULL
)	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
characteristics	NULL
of	NULL
the	NULL
VD	NULL
;	NULL
receptors	NULL
isolated	NULL
by	NULL
extraction	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
with	NULL
buffers	NULL
containing	NULL
300	NULL
mm	NULL
KCl	NULL
.	NULL

These	NULL
techniques	NULL
allow	NULL
the	NULL
receptor	NULL
to	NULL
be	NULL
released	NULL
from	NULL
the	NULL
nucleus	NULL
into	NULL
the	NULL
cytosolic	NULL
fraction	NULL
and	NULL
may	NULL
be	NULL
a	NULL
more	NULL
accurate	NULL
and	NULL
direct	NULL
measure	NULL
of	NULL
VD	NULL
;	NULL
-receptor	NULL
interactions	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
illustrates	NULL
the	NULL
saturation	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
and	NULL
Scatchard	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

18	NULL
)	NULL
of	NULL
the	NULL
binding	NULL
data	NULL
and	NULL
indicates	NULL
that	NULL
RW	NULL
Leu-4	NULL
cells	NULL
contain	NULL
approximately	NULL
2300	NULL
receptors/cell	NULL
with	NULL
a	NULL
K	NULL
,	NULL
of	NULL
0.21	NULL
nm	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
Marker	NULL
Enzyme	NULL
25-D	NULL
;	NULL
-24R-Hydroxylase	NULL
.	NULL

Treatment	NULL
of	NULL
normal	NULL
target	NULL
tissues	NULL
with	NULL
VD	NULL
;	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
the	NULL
synthesis	NULL
of	NULL
the	NULL
enzyme	NULL
24-hydroxylase	NULL
which	NULL
converts	NULL
25-D	NULL
;	NULL
and	NULL
VD	NULL
;	NULL
into	NULL
24	NULL
R,25-D	NULL
;	NULL
and	NULL
14,24	NULL
R,25-D	NULL
;	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
if	NULL
RW	NULL
Leu-4	NULL
cells	NULL
responded	NULL
to	NULL
this	NULL
hormone	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
we	NULL
measured	NULL
the	NULL
induction	NULL
of	NULL
this	NULL
enzyme	NULL
.	NULL

Table	NULL
2	NULL
demonstrates	NULL
that	NULL
treatment	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
with	NULL
50	NULL
nM	NULL
VD	NULL
;	NULL
for	NULL
16	NULL
to	NULL
24	NULL
h	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
this	NULL
enzyme	NULL
activity	NULL
by	NULL
5-	NULL
to	NULL
6-fold	NULL
over	NULL
that	NULL
found	NULL
in	NULL
uninduced	NULL
cells	NULL
or	NULL
in	NULL
the	NULL
no	NULL
cell	NULL
control	NULL
.	NULL

Inhibition	NULL
of	NULL
Proliferation	NULL
of	NULL
RWLeu-4	NULL
Cells	NULL
by	NULL
VD	NULL
;	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
VD	NULL
;	NULL
can	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
other	NULL
leukemia	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HL-60	NULL
and	NULL
U937	NULL
(	NULL
4	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
response	NULL
of	NULL
RWLeu-4	NULL
cell	NULL
proliferation	NULL
to	NULL
VD	NULL
;	NULL
treatment	NULL
.	NULL

RW	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
VD	NULL
;	NULL
for	NULL
1-4	NULL
days	NULL
and	NULL
the	NULL
total	NULL
viable	NULL
cell	NULL
number	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Fig	NULL
.	NULL

24	NULL
shows	NULL
that	NULL
treatment	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
with	NULL
VD	NULL
;	NULL
for	NULL
3-4	NULL
days	NULL
inhibited	NULL
RW	NULL
Leu-4	NULL
proliferation	NULL
with	NULL
an	NULL
EDs	NULL
,	NULL
of	NULL
3.5-7	NULL
nm	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
that	NULL
low	NULL
doses	NULL
of	NULL
VD	NULL
;	NULL
reproducibly	NULL
stimulated	NULL
cell	NULL
proliferation	NULL
at	NULL
24	NULL
h	NULL
by	NULL
approximately	NULL
20	NULL
%	NULL
above	NULL
that	NULL
of	NULL
untreated	NULL
control	NULL
cells	NULL
.	NULL

Effects	NULL
of	NULL
VD	NULL
,	NULL
on	NULL
Differentiation	NULL
of	NULL
RWLeu-4	NULL
Cells	NULL
into	NULL
Mature	NULL
Myeloid	NULL
Cells	NULL
.	NULL

During	NULL
treatment	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
with	NULL
VD	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
the	NULL
morphology	NULL
of	NULL
the	NULL
RW	NULL
cells	NULL
changed	NULL
;	NULL
many	NULL
cells	NULL
became	NULL
adherent	NULL
,	NULL
the	NULL
nuclei	NULL
became	NULL
lobed	NULL
rather	NULL
than	NULL
round	NULL
,	NULL
and	NULL
the	NULL
cytoplasmic	NULL
membranes	NULL
became	NULL
ruffled	NULL
,	NULL
sending	NULL
out	NULL
pseudopod-like	NULL
processes	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
those	NULL
cells	NULL
that	NULL
remained	NULL
in	NULL
suspension	NULL
formed	NULL
large	NULL
clumps	NULL
of	NULL
cells	NULL
.	NULL

We	NULL
therefore	NULL
determined	NULL
the	NULL
correlation	NULL
between	NULL
these	NULL
morphological	NULL
changes	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
differentiated	NULL
characteristics	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

One	NULL
of	NULL
the	NULL
markers	NULL
of	NULL
myelomonocytic	NULL
differentiation	NULL
is	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
cells	NULL
to	NULL
reduce	NULL
tetrazolium	NULL
dyes	NULL
,	NULL
forming	NULL
black	NULL
formazan	NULL
granules	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

Fig	NULL
.	NULL

2B	NULL
illustrates	NULL
the	NULL
results	NULL
of	NULL
an	NULL
experiment	NULL
in	NULL
which	NULL
we	NULL
measured	NULL
the	NULL
ability	NULL
of	NULL
VD	NULL
;	NULL
-treated	NULL
RW	NULL
Leu-4	NULL
cells	NULL
to	NULL
reduce	NULL
NBT	NULL
.	NULL

NBT	NULL
reduction	NULL
was	NULL
not	NULL
particularly	NULL
evident	NULL
by	NULL
light	NULL
microscopic	NULL
examination	NULL
after	NULL
1	NULL
or	NULL
2	NULL
days	NULL
,	NULL
but	NULL
after	NULL
3	NULL
days	NULL
of	NULL
incubation	NULL
with	NULL
5	NULL
nm	NULL
VD	NULL
;	NULL
,	NULL
50	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
displayed	NULL
this	NULL
differentiated	NULL
characteristic	NULL
.	NULL

After	NULL
4	NULL
and	NULL
5	NULL
days	NULL
of	NULL
treatment	NULL
with	NULL
VD	NULL
;	NULL
,	NULL
>	NULL
90	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
the	NULL
culture	NULL
were	NULL
NBT	NULL
positive	NULL
.	NULL

In	NULL
order	NULL
to	NULL
further	NULL
define	NULL
the	NULL
VD	NULL
;	NULL
-induced	NULL
maturation	NULL
of	NULL
RWLeu-4	NULL
cells	NULL
,	NULL
we	NULL
analyzed	NULL
hormone-treated	NULL
cells	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
antigens	NULL
that	NULL
are	NULL
characteristic	NULL
of	NULL
mature	NULL
myelomonocytic	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Murine	NULL
monoclonal	NULL
antibodies	NULL
reactive	NULL
with	NULL
T8	NULL
(	NULL
CD8	NULL
)	NULL
and	NULL
8	NULL
;	NULL
-microglobulin	NULL
served	NULL
as	NULL
negative	NULL
and	NULL
positive	NULL
controls	NULL
,	NULL
respectively	NULL
.	NULL

HLA-DR	NULL
(	NULL
Ia	NULL
)	NULL
antigens	NULL
were	NULL
not	NULL
expressed	NULL
on	NULL
RWLeu-4	NULL
,	NULL
nor	NULL
was	NULL
expression	NULL
induced	NULL
by	NULL
VD	NULL
;	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
myelomonocytic	NULL
markers	NULL
3089	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

1a,25-DIHYDROXYVITAMIN	NULL
D	NULL
;	NULL
,	NULL
EFFECTS	NULL
ON	NULL
CML	NULL
CELLS	NULL
2.5E-11	NULL
0.05	NULL
2E-11	NULL
0.04	NULL
<	NULL
Q	NULL
L5B-11	NULL
0.03	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Saturation	NULL
and	NULL
Scatchard	NULL
analysis	NULL
8	NULL
of	NULL
[	NULL
Â°HJVD	NULL
;	NULL
binding	NULL
.	NULL

Binding	NULL
in	NULL
high	NULL
salt	NULL
cy-	NULL
m	NULL
to	NULL
tosolic	NULL
extracts	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
E	NULL
5	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Nonspecific	NULL
bind-	NULL
n	NULL
ing	NULL
,	NULL
determined	NULL
by	NULL
isotope	NULL
dilution	NULL
,	NULL
was	NULL
sub-	NULL
Ã©	NULL
1EA11	NULL
0.02	NULL
tracted	NULL
from	NULL
total	NULL
binding	NULL
(	NULL
St	NULL
)	NULL
to	NULL
give	NULL
specific	NULL
E-binding	NULL
(	NULL
S5	NULL
)	NULL
.	NULL

4	NULL
,	NULL
saturation	NULL
of	NULL
VD	NULL
;	NULL
binding	NULL
;	NULL
2	NULL
,	NULL
g	NULL
Scatchard	NULL
analysis	NULL
of	NULL
cytosolic	NULL
binding	NULL
.	NULL

D	NULL
m	NULL
5E-12	NULL
0.01	NULL
0	NULL
1	NULL
|	NULL
1	NULL
1	NULL
1	NULL
0	NULL
1	NULL
1	NULL
F	NULL
1	NULL
*	NULL
_	NULL
``	NULL
y	NULL
``	NULL
g	NULL
``	NULL
g	NULL
Â»	NULL
``	NULL
.g	NULL
``	NULL
je	NULL
``	NULL
y*	NULL
s	NULL
``	NULL
g	NULL
``	NULL
g*	NULL
SUBSTRATE	NULL
ADDED	NULL
(	NULL
M	NULL
)	NULL
Sb	NULL
(	NULL
M	NULL
)	NULL
Table	NULL
2	NULL
Induction	NULL
of	NULL
24R-hydroxylase	NULL
activity	NULL
RWLeu-4	NULL
cells	NULL
(	NULL
10Â°	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
16-18	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
50	NULL
nm	NULL
VD	NULL
,	NULL
in	NULL
serum-free	NULL
media	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
harvested	NULL
,	NULL
excess	NULL
inducer	NULL
was	NULL
washed	NULL
out	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
[	NULL
Â°H	NULL
]	NULL
25-D	NULL
;	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37Â°C	NULL
.	NULL

Internal	NULL
standards	NULL
(	NULL
25-D	NULL
;	NULL
and	NULL
24R,25-D	NULL
;	NULL
)	NULL
were	NULL
then	NULL
added	NULL
,	NULL
and	NULL
vitamin	NULL
D	NULL
;	NULL
metabolites	NULL
were	NULL
analyzed	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

No	NULL
cell	NULL
controls	NULL
were	NULL
identical	NULL
reactions	NULL
performed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
cells	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
mean	NULL
+	NULL
SE	NULL
(	NULL
in	NULL
parentheses	NULL
)	NULL
where	NULL
applicable	NULL
.	NULL

NA	NULL
,	NULL
not	NULL
applicable	NULL
.	NULL

Cells	NULL
VD	NULL
;	NULL
pmol/million	NULL
cells	NULL
No	NULL
cell	NULL
control	NULL
-	NULL
1.78	NULL
(	NULL
NA	NULL
)	NULL
+	NULL
1.78	NULL
(	NULL
NA	NULL
)	NULL
RWLeu-4	NULL
-	NULL
1.65	NULL
(	NULL
0.15	NULL
)	NULL
+	NULL
11.95	NULL
(	NULL
1.05	NULL
)	NULL
MoS	NULL
,	NULL
Mol	NULL
,	NULL
and	NULL
My7	NULL
(	NULL
CDw13	NULL
)	NULL
(	NULL
32-34	NULL
)	NULL
are	NULL
constitutively	NULL
expressed	NULL
at	NULL
moderate	NULL
levels	NULL
.	NULL

Expression	NULL
of	NULL
Mol	NULL
increased	NULL
significantly	NULL
(	NULL
P	NULL
=	NULL
0.004	NULL
)	NULL
after	NULL
treatment	NULL
with	NULL
VD	NULL
;	NULL
,	NULL
while	NULL
MoS	NULL
and	NULL
My7	NULL
induction	NULL
was	NULL
variable	NULL
and	NULL
not	NULL
significant	NULL
(	NULL
P	NULL
>	NULL
0.5	NULL
)	NULL
.	NULL

Mo3	NULL
,	NULL
a	NULL
monocyte-specific	NULL
activation	NULL
antigen	NULL
,	NULL
was	NULL
marginally	NULL
and	NULL
variably	NULL
expressed	NULL
prior	NULL
to	NULL
and	NULL
after	NULL
differentiation	NULL
(	NULL
P	NULL
>	NULL
0.5	NULL
)	NULL
,	NULL
while	NULL
Mo2	NULL
,	NULL
a	NULL
monocyte/macrophage	NULL
specific	NULL
antigen	NULL
not	NULL
present	NULL
on	NULL
untreated	NULL
RW	NULL
Leu-4	NULL
cells	NULL
,	NULL
was	NULL
markedly	NULL
induced	NULL
by	NULL
VD	NULL
,	NULL
(	NULL
P	NULL
=	NULL
0.004	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
demonstrate	NULL
that	NULL
VD	NULL
;	NULL
causes	NULL
the	NULL
RWLeu-4	NULL
cell	NULL
line	NULL
to	NULL
mature	NULL
from	NULL
an	NULL
undifferentiated	NULL
myelomonocytic	NULL
cell	NULL
to	NULL
a	NULL
differentiated	NULL
monocyte/	NULL
macrophage	NULL
cell	NULL
but	NULL
may	NULL
not	NULL
result	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
cell	NULL
line	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
Mo3	NULL
antigen	NULL
.	NULL

This	NULL
observation	NULL
was	NULL
corroborated	NULL
by	NULL
experiments	NULL
measuring	NULL
another	NULL
indicator	NULL
of	NULL
monocyte/macrophage	NULL
activation	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
to	NULL
phagocytize	NULL
antigen-coated	NULL
RBC	NULL
.	NULL

While	NULL
RWLeu-4	NULL
cells	NULL
exhibit	NULL
a	NULL
low	NULL
level	NULL
of	NULL
phagocytosis	NULL
of	NULL
human	NULL
RBC	NULL
,	NULL
treatment	NULL
with	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
for	NULL
3	NULL
days	NULL
did	NULL
not	NULL
increase	NULL
this	NULL
activity	NULL
when	NULL
measured	NULL
by	NULL
light	NULL
microscopic	NULL
examination	NULL
of	NULL
phagocytosis	NULL
or	NULL
by	NULL
uptake	NULL
of	NULL
*'Cr-loaded	NULL
RBC	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
Incorporation	NULL
by	NULL
VD	NULL
;	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
shows	NULL
the	NULL
dose	NULL
response	NULL
and	NULL
kinetics	NULL
of	NULL
the	NULL
inhibition	NULL
of	NULL
DNA	NULL
synthesis	NULL
by	NULL
VD	NULL
;	NULL
,	NULL
in	NULL
RW	NULL
Leu-4	NULL
cells	NULL
.	NULL

There	NULL
was	NULL
a	NULL
reproducible	NULL
increase	NULL
in	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
at	NULL
low	NULL
doses	NULL
or	NULL
early	NULL
time	NULL
points	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
dose-dependent	NULL
inhibition	NULL
of	NULL
DNA	NULL
synthesis	NULL
(	NULL
ED	NULL
;	NULL
,	NULL
=3-10	NULL
nm	NULL
)	NULL
.	NULL

Concentrations	NULL
of	NULL
VD	NULL
;	NULL
greater	NULL
than	NULL
50	NULL
nm	NULL
inhibited	NULL
DNA	NULL
synthesis	NULL
by	NULL
as	NULL
much	NULL
as	NULL
90	NULL
%	NULL
.	NULL

TPA	NULL
was	NULL
a	NULL
more	NULL
potent	NULL
inhibitor	NULL
of	NULL
DNA	NULL
synthesis	NULL
than	NULL
VD	NULL
;	NULL
(	NULL
EDs	NULL
,	NULL
between	NULL
0.2	NULL
and	NULL
0.4	NULL
nm	NULL
)	NULL
,	NULL
and	NULL
displayed	NULL
more	NULL
rapid	NULL
kinetics	NULL
,	NULL
showing	NULL
strong	NULL
inhibition	NULL
within	NULL
24	NULL
h	NULL
after	NULL
the	NULL
initiation	NULL
of	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

RNA	NULL
and	NULL
protein	NULL
synthesis	NULL
were	NULL
also	NULL
inhibited	NULL
by	NULL
VD	NULL
;	NULL
treatment	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
.	NULL

Protein	NULL
synthesis	NULL
was	NULL
inhibited	NULL
by	NULL
as	NULL
much	NULL
as	NULL
60	NULL
%	NULL
after	NULL
1	NULL
day	NULL
of	NULL
treatment	NULL
and	NULL
by	NULL
greater	NULL
than	NULL
80	NULL
%	NULL
at	NULL
longer	NULL
times	NULL
,	NULL
with	NULL
an	NULL
ED	NULL
;	NULL
,	NULL
of	NULL
7	NULL
to	NULL
10	NULL
nm	NULL
.	NULL

Total	NULL
RNA	NULL
synthesis	NULL
was	NULL
not	NULL
as	NULL
affected	NULL
by	NULL
VD	NULL
;	NULL
treatment	NULL
,	NULL
showing	NULL
an	NULL
EDs	NULL
,	NULL
of	NULL
greater	NULL
than	NULL
20	NULL
nm	NULL
and	NULL
less	NULL
than	NULL
80	NULL
%	NULL
inhibition	NULL
even	NULL
after	NULL
4	NULL
days	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
c-myc	NULL
mRNA	NULL
.	NULL

Northern	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
isolated	NULL
from	NULL
RW	NULL
cells	NULL
showed	NULL
that	NULL
high	NULL
levels	NULL
of	NULL
c-myc	NULL
RNA	NULL
are	NULL
constitutively	NULL
expressed	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
top	NULL
,	NULL
0	NULL
hour	NULL
time	NULL
point	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
shows	NULL
an	NULL
autoradiographic	NULL
analysis	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
treatment	NULL
on	NULL
c-myc	NULL
expression	NULL
in	NULL
RWLeu-4	NULL
cells	NULL
.	NULL

Within	NULL
0.5	NULL
h	NULL
after	NULL
treatment	NULL
with	NULL
VD	NULL
;	NULL
,	NULL
c-myc-specific	NULL
RNA	NULL
sharply	NULL
increased	NULL
in	NULL
quantity	NULL
then	NULL
decreased	NULL
to	NULL
barely	NULL
detectable	NULL
levels	NULL
within	NULL
4	NULL
h.	NULL
The	NULL
bottom	NULL
of	NULL
Fig	NULL
.	NULL

6	NULL
is	NULL
an	NULL
autora-diogram	NULL
of	NULL
the	NULL
same	NULL
blot	NULL
after	NULL
reprobing	NULL
with	NULL
a	NULL
S-actin	NULL
probe	NULL
and	NULL
shows	NULL
that	NULL
approximately	NULL
equal	NULL
amounts	NULL
of	NULL
RNA	NULL
were	NULL
loaded	NULL
onto	NULL
the	NULL
gel	NULL
in	NULL
all	NULL
lanes	NULL
.	NULL

Effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
c-abl-associated	NULL
Tyrosine	NULL
Kinase	NULL
Activity	NULL
.	NULL

Since	NULL
the	NULL
presence	NULL
of	NULL
constitutive	NULL
p210	NULL
``	NULL
*~*	NULL
``	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
the	NULL
initial	NULL
transformation	NULL
of	NULL
CML	NULL
cells	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
,	NULL
treatment	NULL
on	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
in	NULL
RW	NULL
Leu-4	NULL
cells	NULL
.	NULL

While	NULL
no	NULL
difference	NULL
in	NULL
the	NULL
steady	NULL
state	NULL
level	NULL
of	NULL
phosphotyrosine-containing	NULL
proteins	NULL
could	NULL
be	NULL
detected	NULL
after	NULL
in	NULL
vivo	NULL
P	NULL
labeling	NULL
of	NULL
VD	NULL
;	NULL
treated	NULL
or	NULL
control	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
there	NULL
were	NULL
differences	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
protein	NULL
kinase	NULL
activity	NULL
associated	NULL
with	NULL
proteins	NULL
partially	NULL
purified	NULL
by	NULL
immunoprecipitation	NULL
with	NULL
anti-c-ab/	NULL
antibodies	NULL
.	NULL

Fig	NULL
.	NULL

7	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
an	NULL
in	NULL
vitro	NULL
protein	NULL
kinase	NULL
assay	NULL
using	NULL
extracts	NULL
of	NULL
VD	NULL
,	NULL
or	NULL
control	NULL
cells	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
,	NULL
treatment	NULL
of	NULL
RWLeu-4	NULL
cells	NULL
with	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
for	NULL
16	NULL
to	NULL
18	NULL
h	NULL
decreased	NULL
the	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
of	NULL
proteins	NULL
that	NULL
cross-react	NULL
with	NULL
rabbit	NULL
anti-abl	NULL
antibodies	NULL
by	NULL
approximately	NULL
50	NULL
%	NULL
.	NULL

No	NULL
differences	NULL
were	NULL
3090	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

1	NULL
Â«	NULL
,25-DIHYDROXYVITAMIN	NULL
D	NULL
;	NULL
,	NULL
EFFECTS	NULL
ON	NULL
CML	NULL
CELLS	NULL
120	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Dose	NULL
response	NULL
(	NULL
4	NULL
)	NULL
and	NULL
kinetics	NULL
of	NULL
the	NULL
inhibition	NULL
of	NULL
proliferation	NULL
and	NULL
induction	NULL
of	NULL
monocytic	NULL
characteristics	NULL
(	NULL
NBT	NULL
staining	NULL
)	NULL
(	NULL
B	NULL
)	NULL
in	NULL
100	NULL
RWLeu-4	NULL
cells	NULL
by	NULL
VD	NULL
;	NULL
.	NULL

triplicate	NULL
cultures	NULL
of	NULL
1	NULL
I	NULL
x	NULL
10Â°	NULL
RWLeu-4	NULL
cells	NULL
were	NULL
seeded	NULL
into	NULL
1	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
10-fold	NULL
serial	NULL
dilutions	NULL
of	NULL
VD	NULL
;	NULL
from	NULL
107	NULL
to	NULL
10~	NULL
'	NULL
``	NULL
'	NULL
m	NULL
for	NULL
1-4	NULL
(	NULL
4	NULL
)	NULL
or	NULL
1-5	NULL
(	NULL
B	NULL
)	NULL
days	NULL
.	NULL

Control	NULL
cultures	NULL
received	NULL
diluent	NULL
alone	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
treatment	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
chilled	NULL
for	NULL
30	NULL
min	NULL
,	NULL
suspended	NULL
by	NULL
scraping	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
trypan	NULL
blue	NULL
;	NULL
viable	NULL
cells	NULL
counted	NULL
in	NULL
a	NULL
hemocytometer	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cells	NULL
were	NULL
assayed	NULL
for	NULL
NBT	NULL
reduction	NULL
as	NULL
per	NULL
directions	NULL
provided	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

After	NULL
treatment	NULL
,	NULL
the	NULL
number	NULL
of	NULL
NBT-positive	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
microscopic	NULL
examination	NULL
in	NULL
a	NULL
hemocytometer	NULL
.	NULL

At	NULL
least	NULL
200	NULL
cells	NULL
were	NULL
counted	NULL
per	NULL
culture	NULL
and	NULL
the	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
treated	NULL
cultures	NULL
compared	NULL
to	NULL
the	NULL
control	NULL
cultures	NULL
.	NULL

Viability	NULL
was	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
in	NULL
all	NULL
cultures	NULL
.	NULL

O	NULL
,	NULL
24-h	NULL
treat	NULL
80	NULL
7	NULL
PERCENT	NULL
OF	NULL
CONTROL	NULL
PERCENT	NULL
NBT	NULL
POSITIVE	NULL
CELLS	NULL
ment	NULL
;	NULL
O	NULL
,	NULL
48-h	NULL
treatment	NULL
;	NULL
A	NULL
,	NULL
72-h	NULL
treatment	NULL
;	NULL
M	NULL
,	NULL
40	NULL
96-h	NULL
treatment	NULL
;	NULL
@	NULL
,	NULL
120-h	NULL
treatment	NULL
.	NULL

CONCENTRATION	NULL
(	NULL
M	NULL
)	NULL
e	NULL
*	NULL
%	NULL
@	NULL
h	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Photomicroscopic	NULL
examination	NULL
of	NULL
morphological	NULL
changes	NULL
after	NULL
treatment	NULL
of	NULL
RWLeu-4	NULL
cells	NULL
with	NULL
VD	NULL
;	NULL
;	NULL
RWLeu-4	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
photomicrographs	NULL
taken	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

4	NULL
,	NULL
mock-treated	NULL
RWLeu-4	NULL
cells	NULL
.	NULL

x500	NULL
.	NULL

8	NULL
,	NULL
RWLeu-4	NULL
cells	NULL
treated	NULL
for	NULL
4	NULL
days	NULL
with	NULL
50	NULL
nM	NULL
VD	NULL
;	NULL
.	NULL

x	NULL
400.	NULL
detected	NULL
in	NULL
the	NULL
level	NULL
of	NULL
ber-abl	NULL
mRNA	NULL
after	NULL
VD	NULL
;	NULL
,	NULL
treatment	NULL
,	NULL
possibly	NULL
reflecting	NULL
the	NULL
very	NULL
rapid	NULL
turnover	NULL
of	NULL
ber-abl	NULL
mRNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

w	NULL
Â»	NULL
``	NULL
Â»	NULL
4	NULL
10Â°	NULL
10	NULL
%	NULL
1	NULL
``	NULL
1+	NULL
10	NULL
B	NULL
10	NULL
}	NULL
04	NULL
1	NULL
Â®	NULL
10Â°	NULL
10	NULL
%	NULL
107	NULL
10	NULL
%	NULL
CONCENTRATION	NULL
(	NULL
M	NULL
)	NULL
100	NULL
=	NULL
40	NULL
|	NULL
20	NULL
|	NULL
MZ	NULL
)	NULL
TB	NULL
m	NULL
&	NULL
_	NULL
MOL	NULL
-	NULL
Mo2	NULL
ANTIBODY	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Analysis	NULL
of	NULL
mature	NULL
monocyte-specific	NULL
cell	NULL
surface	NULL
antigen	NULL
expression	NULL
;	NULL
2	NULL
x	NULL
10Â°	NULL
RWLeu-4	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
for	NULL
72	NULL
h.	NULL
Control	NULL
cultures	NULL
were	NULL
grown	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
diluent	NULL
alone	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
cell	NULL
surface	NULL
antigen	NULL
expression	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Results	NULL
represent	NULL
an	NULL
average	NULL
of	NULL
at	NULL
least	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

O	NULL
,	NULL
Control	NULL
;	NULL
0	NULL
,	NULL
24	NULL
h	NULL
;	NULL
8	NULL
,	NULL
48	NULL
h	NULL
;	NULL
&	NULL
,	NULL
72	NULL
h.	NULL
PERCENT	NULL
POSTIVE	NULL
CELLS	NULL
Moe	NULL
_	NULL
MoS	NULL
DISCUSSION	NULL
The	NULL
studies	NULL
reported	NULL
here	NULL
demonstrate	NULL
that	NULL
the	NULL
immature	NULL
,	NULL
Ph'-positive	NULL
myelomonocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
RWLeu-4	NULL
,	NULL
possesses	NULL
a	NULL
high	NULL
affinity	NULL
receptor	NULL
for	NULL
VD	NULL
;	NULL
with	NULL
an	NULL
equilibrium	NULL
dissociation	NULL
constant	NULL
of	NULL
0.21-0.33	NULL
nm	NULL
present	NULL
at	NULL
approximately	NULL
2300-3300	NULL
copies/cell	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
similar	NULL
to	NULL
those	NULL
reported	NULL
in	NULL
other	NULL
leukemic	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HL-60	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
.	NULL

RWLeu-4	NULL
cells	NULL
respond	NULL
to	NULL
VD	NULL
;	NULL
treatment	NULL
by	NULL
expressing	NULL
24	NULL
R-hydroxylase	NULL
activity	NULL
,	NULL
characteristic	NULL
of	NULL
receptor-mediated	NULL
processes	NULL
found	NULL
in	NULL
both	NULL
the	NULL
classical	NULL
and	NULL
nonclassical	NULL
target	NULL
tissues	NULL
for	NULL
VD	NULL
;	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
of	NULL
exposure	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
to	NULL
VD	NULL
;	NULL
,	NULL
macromolecular	NULL
synthesis	NULL
is	NULL
markedly	NULL
inhibited	NULL
and	NULL
the	NULL
cells	NULL
differentiate	NULL
along	NULL
a	NULL
monocyte/macrophage	NULL
pathway	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
morphological	NULL
examination	NULL
,	NULL
NBT	NULL
staining	NULL
,	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
macrophage-	NULL
or	NULL
monocyte-specific	NULL
cell	NULL
surface	NULL
3091	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

1	NULL
Â«	NULL
,25-DIHYDROXYVITAMIN	NULL
D	NULL
,	NULL
EFFECTS	NULL
ON	NULL
CML	NULL
CELLS	NULL
120	NULL
PERCENT	NULL
OF	NULL
CONTROL	NULL
8	NULL
0	NULL
10-11	NULL
10Â°19	NULL
10Â°Â°	NULL
106	NULL
CONCENTRATION	NULL
OF	NULL
VD3	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Kinetics	NULL
and	NULL
dose	NULL
response	NULL
of	NULL
the	NULL
inhibition	NULL
of	NULL
[	NULL
Â°HJthymidine	NULL
incorporation	NULL
by	NULL
VD	NULL
;	NULL
.	NULL

Triplicate	NULL
cultures	NULL
of	NULL
2	NULL
x	NULL
10Â°	NULL
ceils/ml	NULL
were	NULL
grown	NULL
in	NULL
200	NULL
Ll	NULL
of	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2-fold	NULL
serial	NULL
dilutions	NULL
of	NULL
VD	NULL
;	NULL
ranging	NULL
in	NULL
concentration	NULL
from	NULL
100	NULL
nm	NULL
to	NULL
10	NULL
pm	NULL
for	NULL
24	NULL
h	NULL
(	NULL
C	NULL
)	NULL
,	NULL
48	NULL
h	NULL
(	NULL
0	NULL
)	NULL
,	NULL
72	NULL
h	NULL
(	NULL
A	NULL
)	NULL
,	NULL
or	NULL
96	NULL
h	NULL
(	NULL
@	NULL
.	NULL

Control	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
plus	NULL
10	NULL
%	NULL
FCS	NULL
alone	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
incubation	NULL
the	NULL
cells	NULL
were	NULL
pulsed	NULL
for	NULL
4	NULL
h	NULL
with	NULL
0.5	NULL
uCi	NULL
of	NULL
[	NULL
5-methyl	NULL
>	NULL
H	NULL
}	NULL
-thymidine	NULL
before	NULL
harvesting	NULL
onto	NULL
glass	NULL
fiber	NULL
filters	NULL
using	NULL
an	NULL
automatic	NULL
cell	NULL
harvester	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
control	NULL
cell	NULL
[	NULL
'	NULL
H	NULL
]	NULL
thymi-dine	NULL
incorporation	NULL
at	NULL
each	NULL
time	NULL
.	NULL

Control	NULL
cell	NULL
incorporation	NULL
averaged	NULL
80,000	NULL
cpm	NULL
and	NULL
background	NULL
from	NULL
a	NULL
no	NULL
cell	NULL
control	NULL
was	NULL
80	NULL
cpm	NULL
.	NULL

LENGTH	NULL
OF	NULL
VD3	NULL
AA	NULL
#	NULL
14	NULL
|a	NULL
|	NULL
s	NULL
|	NULL
Â£	NULL
Tae	NULL
L	NULL
Tas	NULL
T	NULL
TREATMENT	NULL
=n	NULL
in	NULL
|	NULL
2	NULL
n	NULL
fos	NULL
<	NULL
p	NULL
mye	NULL
Actin	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
VD	NULL
,	NULL
treatment	NULL
on	NULL
c-myc	NULL
RNA	NULL
levels	NULL
.	NULL

RWLeu-4	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nm	NULL
VD	NULL
,	NULL
,	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
at	NULL
each	NULL
time	NULL
point	NULL
and	NULL
analyzed	NULL
by	NULL
hybridization	NULL
to	NULL
specific	NULL
probes	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
same	NULL
filter	NULL
was	NULL
successively	NULL
probed	NULL
with	NULL
random	NULL
primed	NULL
c-myc	NULL
complementary	NULL
DNA	NULL
(	NULL
top	NULL
)	NULL
or	NULL
S-actin	NULL
complementary	NULL
DNA	NULL
(	NULL
bottom	NULL
)	NULL
as	NULL
a	NULL
control	NULL
for	NULL
equal	NULL
loading	NULL
of	NULL
RNA	NULL
.	NULL

antigens	NULL
.	NULL

Taken	NULL
together	NULL
these	NULL
findings	NULL
indicate	NULL
that	NULL
the	NULL
RWLeu-4	NULL
cells	NULL
possess	NULL
a	NULL
functional	NULL
receptor-effector	NULL
system	NULL
for	NULL
VD	NULL
;	NULL
and	NULL
that	NULL
VD	NULL
;	NULL
is	NULL
capable	NULL
of	NULL
inducing	NULL
profound	NULL
changes	NULL
in	NULL
the	NULL
activity	NULL
,	NULL
morphology	NULL
,	NULL
and	NULL
differentiation	NULL
of	NULL
these	NULL
leukemia	NULL
cells	NULL
.	NULL

CML	NULL
is	NULL
a	NULL
disease	NULL
in	NULL
which	NULL
a	NULL
defect	NULL
in	NULL
maturation	NULL
and	NULL
terminal	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
leads	NULL
to	NULL
an	NULL
accumulation	NULL
of	NULL
both	NULL
mature	NULL
and	NULL
immature	NULL
Ph'-positive	NULL
leukemia	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
characteristic	NULL
of	NULL
this	NULL
disease	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
the	NULL
acute	NULL
leukemias	NULL
,	NULL
that	NULL
,	NULL
over	NULL
a	NULL
prolonged	NULL
period	NULL
of	NULL
time	NULL
,	NULL
progressively	NULL
more	NULL
immature	NULL
forms	NULL
predominate	NULL
until	NULL
a	NULL
rapidly	NULL
occurring	NULL
and	NULL
fatal	NULL
``	NULL
blast	NULL
crisis	NULL
``	NULL
intervenes	NULL
.	NULL

Of	NULL
interest	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
agents	NULL
such	NULL
as	NULL
a-interferon	NULL
and	NULL
1-8-p-arabinofuranosylcytosine	NULL
,	NULL
which	NULL
can	NULL
cause	NULL
in	NULL
vitro	NULL
maturation	NULL
and	NULL
differentiation	NULL
of	NULL
CML	NULL
cells	NULL
,	NULL
have	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
remissions	NULL
in	NULL
patients	NULL
during	NULL
chronic	NULL
phase	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
it	NULL
is	NULL
noteworthy	NULL
that	NULL
nude	NULL
8,000	NULL
|-	NULL
|	NULL
6,000	NULL
CPM	NULL
2,000	NULL
|	NULL
CONTROL	NULL
VD3	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Effects	NULL
of	NULL
VD	NULL
,	NULL
treatment	NULL
on	NULL
p210	NULL
``	NULL
``	NULL
**-associated	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
.	NULL

Exponentially	NULL
growing	NULL
RW	NULL
Leu-4	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nm	NULL
VD	NULL
;	NULL
or	NULL
diluent	NULL
alone	NULL
(	NULL
control	NULL
)	NULL
for	NULL
16-18	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
then	NULL
extracted	NULL
and	NULL
immuno-precipitated	NULL
,	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

mice	NULL
inoculated	NULL
s.c.	NULL
with	NULL
RWLeu-4	NULL
cells	NULL
form	NULL
tumors	NULL
which	NULL
regress	NULL
in	NULL
vivo	NULL
in	NULL
response	NULL
to	NULL
certain	NULL
differentiation	NULL
agents	NULL
(	NULL
38	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
pharmacological	NULL
induction	NULL
of	NULL
maturation	NULL
or	NULL
differentiation	NULL
in	NULL
chronic	NULL
phase	NULL
CML	NULL
can	NULL
reduce	NULL
the	NULL
proliferation	NULL
and	NULL
accumulation	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
and	NULL
may	NULL
lead	NULL
to	NULL
prolonged	NULL
remissions	NULL
.	NULL

As	NULL
we	NULL
have	NULL
shown	NULL
for	NULL
the	NULL
RW	NULL
Leu-4	NULL
cell	NULL
line	NULL
and	NULL
as	NULL
has	NULL
been	NULL
demonstrated	NULL
previously	NULL
with	NULL
the	NULL
HL-60	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
and	NULL
the	NULL
U937	NULL
monoblastic	NULL
celi	NULL
line	NULL
,	NULL
VD	NULL
;	NULL
is	NULL
an	NULL
effective	NULL
inducer	NULL
of	NULL
monocyte	NULL
differentiation	NULL
.	NULL

VD	NULL
;	NULL
induces	NULL
en-zymatic	NULL
and	NULL
surface	NULL
antigen	NULL
changes	NULL
characteristic	NULL
of	NULL
mono-cytes	NULL
in	NULL
all	NULL
three	NULL
cell	NULL
types	NULL
.	NULL

It	NULL
induces	NULL
both	NULL
RW	NULL
Leu-4	NULL
and	NULL
HL-60	NULL
to	NULL
develop	NULL
increased	NULL
NBT	NULL
reduction	NULL
and	NULL
expression	NULL
of	NULL
monocytic	NULL
surface	NULL
antigens	NULL
.	NULL

Interestingly	NULL
,	NULL
neither	NULL
RWLeu-4	NULL
nor	NULL
HL-60	NULL
cells	NULL
express	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
monocyte	NULL
surface	NULL
antigen	NULL
Mo3	NULL
,	NULL
a	NULL
marker	NULL
of	NULL
monocyte	NULL
activation	NULL
(	NULL
as	NULL
opposed	NULL
to	NULL
differentiation	NULL
)	NULL
after	NULL
exposure	NULL
to	NULL
VD	NULL
;	NULL
.	NULL

This	NULL
is	NULL
further	NULL
substantiated	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
phagocytosis	NULL
of	NULL
antibody-coated	NULL
RBC	NULL
,	NULL
another	NULL
marker	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
monocytes	NULL
,	NULL
is	NULL
not	NULL
increased	NULL
in	NULL
RW	NULL
Leu-4	NULL
cells	NULL
by	NULL
treatment	NULL
with	NULL
VD	NULL
;	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
both	NULL
cell	NULL
types	NULL
differentiate	NULL
in	NULL
response	NULL
to	NULL
treatment	NULL
with	NULL
the	NULL
phorbol	NULL
ester	NULL
,	NULL
TPA	NULL
,	NULL
and	NULL
this	NULL
agent	NULL
does	NULL
induce	NULL
the	NULL
appearance	NULL
of	NULL
Mo3	NULL
.	NULL

While	NULL
HL-60	NULL
and	NULL
RW	NULL
Leu-4	NULL
cells	NULL
have	NULL
similar	NULL
phenotypes	NULL
,	NULL
they	NULL
are	NULL
derived	NULL
from	NULL
genetically	NULL
distinct	NULL
types	NULL
of	NULL
leukemia	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
RW	NULL
Leu-4	NULL
cell	NULL
line	NULL
offers	NULL
a	NULL
unique	NULL
opportunity	NULL
for	NULL
studying	NULL
the	NULL
effects	NULL
of	NULL
differentiation	NULL
agents	NULL
such	NULL
as	NULL
VD	NULL
;	NULL
,	NULL
TPA	NULL
,	NULL
retinoic	NULL
acid	NULL
,	NULL
and	NULL
dimethyl	NULL
sulfoxide	NULL
on	NULL
CML	NULL
.	NULL

Furthermore	NULL
,	NULL
based	NULL
on	NULL
the	NULL
present	NULL
results	NULL
and	NULL
additional	NULL
data	NULL
being	NULL
obtained	NULL
with	NULL
the	NULL
nude	NULL
mouse	NULL
model	NULL
system	NULL
,	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
the	NULL
molecular	NULL
events	NULL
leading	NULL
to	NULL
commitment	NULL
of	NULL
this	NULL
cell	NULL
line	NULL
to	NULL
a	NULL
program	NULL
of	NULL
monocytic	NULL
differentiation	NULL
can	NULL
be	NULL
productively	NULL
studied	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

RWLeu-4	NULL
cells	NULL
grow	NULL
continuously	NULL
in	NULL
culture	NULL
,	NULL
but	NULL
treatment	NULL
with	NULL
low	NULL
doses	NULL
of	NULL
VD	NULL
;	NULL
(	NULL
EDs	NULL
,	NULL
=3-30	NULL
nm	NULL
)	NULL
inhibit	NULL
their	NULL
proliferation	NULL
,	NULL
DNA	NULL
,	NULL
RNA	NULL
,	NULL
and	NULL
protein	NULL
synthesis	NULL
in	NULL
a	NULL
time-	NULL
and	NULL
dose-dependent	NULL
fashion	NULL
.	NULL

Similar	NULL
effects	NULL
are	NULL
induced	NULL
by	NULL
TPA	NULL
.	NULL

How-ever	NULL
,	NULL
TPA	NULL
does	NULL
not	NULL
compete	NULL
with	NULL
VD	NULL
;	NULL
for	NULL
binding	NULL
to	NULL
its	NULL
receptor	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
therefore	NULL
,	NULL
TPA	NULL
does	NULL
not	NULL
exert	NULL
its	NULL
effects	NULL
through	NULL
the	NULL
VD	NULL
;	NULL
receptor	NULL
.	NULL

It	NULL
is	NULL
thought	NULL
that	NULL
the	NULL
activity	NULL
of	NULL
phorbol	NULL
esters	NULL
is	NULL
mediated	NULL
through	NULL
binding	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
phospholipid-dependent	NULL
PK	NULL
,	NULL
(	NULL
39	NULL
)	NULL
.	NULL

At	NULL
present	NULL
,	NULL
there	NULL
are	NULL
conflicting	NULL
reports	NULL
on	NULL
the	NULL
effect	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
this	NULL
enzyme	NULL
activity	NULL
:	NULL
3092	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

1a,25-DIHYDROXYVITAMIN	NULL
D	NULL
,	NULL
EFFECTS	NULL
ON	NULL
CML	NULL
CELLS	NULL
Kuroki	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40	NULL
)	NULL
have	NULL
shown	NULL
in	NULL
vitro	NULL
that	NULL
VD	NULL
;	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
partially	NULL
purified	NULL
rat	NULL
brain	NULL
PK	NULL
.	NULL

,	NULL
while	NULL
Ways	NULL
et	NULL
a/	NULL
.	NULL

(	NULL
41	NULL
)	NULL
have	NULL
shown	NULL
in	NULL
vivo	NULL
that	NULL
VD	NULL
;	NULL
treatment	NULL
of	NULL
U937	NULL
cells	NULL
does	NULL
modulate	NULL
the	NULL
activity	NULL
of	NULL
PK	NULL
,	NULL
.	NULL

We	NULL
are	NULL
in	NULL
the	NULL
process	NULL
of	NULL
examining	NULL
the	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
PK	NULL
,	NULL
activity	NULL
in	NULL
RW	NULL
Leu-4	NULL
cells	NULL
in	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
TPA	NULL
and	NULL
VD	NULL
;	NULL
act	NULL
at	NULL
the	NULL
same	NULL
or	NULL
different	NULL
sites	NULL
to	NULL
inhibit	NULL
proliferation	NULL
and	NULL
induce	NULL
differentiation	NULL
.	NULL

Preliminary	NULL
observations	NULL
with	NULL
a	NULL
variant	NULL
of	NULL
RWLeu-4	NULL
(	NULL
RD	NULL
;	NULL
)	NULL
show	NULL
that	NULL
this	NULL
cell	NULL
line	NULL
is	NULL
still	NULL
sensitive	NULL
to	NULL
the	NULL
antiprolif-erative	NULL
effects	NULL
of	NULL
TPA	NULL
,	NULL
strongly	NULL
suggesting	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
two	NULL
agents	NULL
in	NULL
RW	NULL
Leu-4	NULL
cells	NULL
are	NULL
different	NULL
.	NULL

*	NULL
We	NULL
therefore	NULL
believe	NULL
that	NULL
phorbol	NULL
esters	NULL
and	NULL
VD	NULL
;	NULL
act	NULL
via	NULL
independent	NULL
pathways	NULL
or	NULL
at	NULL
different	NULL
sites	NULL
in	NULL
connected	NULL
pathways	NULL
,	NULL
which	NULL
lead	NULL
to	NULL
a	NULL
common	NULL
result	NULL
of	NULL
differentiation	NULL
to	NULL
monocytoid	NULL
cells	NULL
.	NULL

RWLeu-4	NULL
cells	NULL
are	NULL
Ph	NULL
'	NULL
positive	NULL
and	NULL
express	NULL
the	NULL
aberrant	NULL
210kDa	NULL
BCR-ABL	NULL
oncogene	NULL
protein	NULL
(	NULL
p210Â°~**	NULL
)	NULL
characteristic	NULL
of	NULL
CML	NULL
cells	NULL
(	NULL
18	NULL
,	NULL
42-44	NULL
)	NULL
.	NULL

The	NULL
constitutive	NULL
protein-tyrosine	NULL
kinase	NULL
activity	NULL
of	NULL
p210Â°*	NULL
``	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
CML	NULL
,	NULL
although	NULL
its	NULL
exact	NULL
role	NULL
is	NULL
not	NULL
established	NULL
.	NULL

Ph'-positive	NULL
cell	NULL
lines	NULL
and	NULL
peripheral	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
leukocytes	NULL
of	NULL
CML	NULL
patients	NULL
possess	NULL
a	NULL
characteristic	NULL
spectrum	NULL
of	NULL
phosphotyrosy	NULL
!	NULL

proteins	NULL
that	NULL
are	NULL
candidates	NULL
for	NULL
cellular	NULL
substrates	NULL
of	NULL
the	NULL
p210**	NULL
``	NULL
kinase	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
phosphorylation	NULL
of	NULL
one	NULL
or	NULL
more	NULL
of	NULL
these	NULL
cellular	NULL
proteins	NULL
on	NULL
tyrosine	NULL
residues	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
mediating	NULL
proliferation-	NULL
or	NULL
trans-formation-related	NULL
signal	NULL
transduction	NULL
.	NULL

It	NULL
might	NULL
be	NULL
anticipated	NULL
,	NULL
then	NULL
,	NULL
that	NULL
differentiation	NULL
of	NULL
CML	NULL
cells	NULL
would	NULL
be	NULL
correlated	NULL
with	NULL
alterations	NULL
in	NULL
phosphorylation	NULL
of	NULL
one	NULL
or	NULL
more	NULL
of	NULL
the	NULL
physiolog-ically	NULL
relevant	NULL
substrates	NULL
of	NULL
p210	NULL
``	NULL
~*	NULL
``	NULL
.	NULL

Indeed	NULL
,	NULL
changes	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
cellular	NULL
phosphotyrosyl	NULL
proteins	NULL
have	NULL
been	NULL
observed	NULL
in	NULL
RW	NULL
Leu-4	NULL
cells	NULL
induced	NULL
to	NULL
differentiate	NULL
with	NULL
phorbol	NULL
esters	NULL
.	NULL
``	NULL

We	NULL
show	NULL
here	NULL
that	NULL
treatment	NULL
of	NULL
RW	NULL
Leu-4	NULL
cells	NULL
with	NULL
VD	NULL
;	NULL
decreases	NULL
the	NULL
activity	NULL
of	NULL
c-abl-related	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
o-vanadate	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
tyrosine	NULL
phosphatase	NULL
activity	NULL
.	NULL

Â¢-myc	NULL
expression	NULL
has	NULL
been	NULL
correlated	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
cells	NULL
to	NULL
proliferate	NULL
(	NULL
45-47	NULL
)	NULL
.	NULL

While	NULL
transient	NULL
in	NULL
nature	NULL
,	NULL
the	NULL
rapid	NULL
,	NULL
initial	NULL
increase	NULL
in	NULL
myc	NULL
RNA	NULL
levels	NULL
seen	NULL
after	NULL
treatment	NULL
of	NULL
RWLeu-4	NULL
cells	NULL
for	NULL
0.5	NULL
h	NULL
may	NULL
correlate	NULL
with	NULL
the	NULL
stimulation	NULL
of	NULL
DNA	NULL
synthesis	NULL
that	NULL
is	NULL
seen	NULL
with	NULL
low	NULL
doses	NULL
or	NULL
short	NULL
exposure	NULL
to	NULL
VD	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
decrease	NULL
in	NULL
c-myc	NULL
mRNA	NULL
expression	NULL
seen	NULL
at	NULL
later	NULL
times	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
DNA	NULL
synthesis	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
HL-60	NULL
cells	NULL
with	NULL
VD	NULL
;	NULL
suppresses	NULL
proliferation	NULL
(	NULL
4	NULL
,	NULL
36	NULL
)	NULL
and	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
c-myc	NULL
oncogene	NULL
(	NULL
45	NULL
,	NULL
48	NULL
)	NULL
as	NULL
well	NULL
as	NULL
inducing	NULL
differentiation	NULL
into	NULL
mature	NULL
monocyte/macrophage	NULL
like	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
other	NULL
more	NULL
undifferentiated	NULL
leukemia	NULL
model	NULL
systems	NULL
(	NULL
12	NULL
,	NULL
49	NULL
)	NULL
,	NULL
but	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
VD	NULL
;	NULL
inhibits	NULL
proliferation	NULL
and	NULL
induces	NULL
differentiation	NULL
are	NULL
un-known	NULL
.	NULL

We	NULL
are	NULL
in	NULL
the	NULL
process	NULL
of	NULL
determining	NULL
whether	NULL
the	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
c-myc	NULL
expression	NULL
are	NULL
at	NULL
the	NULL
level	NULL
of	NULL
RNA	NULL
synthesis	NULL
or	NULL
stability	NULL
as	NULL
well	NULL
as	NULL
investigating	NULL
the	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
other	NULL
oncogenes	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
the	NULL
application	NULL
of	NULL
molecular	NULL
biological	NULL
and	NULL
recombinant	NULL
DNA	NULL
techniques	NULL
to	NULL
the	NULL
investigation	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
VD	NULL
;	NULL
on	NULL
the	NULL
Ph'-positive	NULL
cell	NULL
line	NULL
,	NULL
RW	NULL
offers	NULL
a	NULL
unique	NULL
opportunity	NULL
to	NULL
elucidate	NULL
the	NULL
molecular	NULL
events	NULL
involved	NULL
in	NULL
the	NULL
development	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

While	NULL
similar	NULL
investigations	NULL
are	NULL
ongoing	NULL
with	NULL
other	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HL-60	NULL
and	NULL
U937	NULL
,	NULL
RW	NULL
Leu-4	NULL
cells	NULL
are	NULL
derived	NULL
from	NULL
a	NULL
genetically	NULL
distinct	NULL
and	NULL
differentiation	NULL
specific	NULL
leukemia	NULL
and	NULL
thus	NULL
offer	NULL
a	NULL
unique	NULL
model	NULL
for	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
studies	NULL
in	NULL
the	NULL
athymic	NULL
mouse	NULL
*	NULL
Manuscript	NULL
in	NULL
preparation	NULL
.	NULL

*	NULL
R.	NULL
D.	NULL
Huhn	NULL
and	NULL
A.	NULL
R.	NULL
Frackelton	NULL
Jr.	NULL
,	NULL
unpublished	NULL
observations	NULL
.	NULL

model	NULL
system	NULL
.	NULL

These	NULL
studies	NULL
should	NULL
provide	NULL
insights	NULL
into	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
VD	NULL
;	NULL
and	NULL
may	NULL
lead	NULL
to	NULL
a	NULL
greater	NULL
understanding	NULL
of	NULL
the	NULL
action	NULL
of	NULL
protooncogene	NULL
function	NULL
in	NULL
differentiating	NULL
systems	NULL
.	NULL

Such	NULL
understanding	NULL
may	NULL
prove	NULL
useful	NULL
in	NULL
developing	NULL
therapies	NULL
for	NULL
chronic	NULL
and	NULL
acute	NULL
leukemias	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Dr.	NULL
Robert	NULL
F.	NULL
Todd	NULL
III	NULL
for	NULL
supplying	NULL
us	NULL
with	NULL
antibodies	NULL
to	NULL
Mo2	NULL
,	NULL
Mo3	NULL
,	NULL
MoS	NULL
,	NULL
and	NULL
Ia	NULL
antigens	NULL
;	NULL
Dr.	NULL
Lee	NULL
Nadler	NULL
for	NULL
antibodies	NULL
to	NULL
B	NULL
,	NULL
-microglobulin	NULL
;	NULL
Dr.	NULL
A.	NULL
Raymond	NULL
Frackelton	NULL
for	NULL
helpful	NULL
discussions	NULL
;	NULL
and	NULL
R.	NULL
Mackie	NULL
Ramsden	NULL
for	NULL
editorial	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Haussler	NULL
,	NULL
M.	NULL
R.	NULL
Vitamin	NULL
D	NULL
receptors	NULL
:	NULL
nature	NULL
and	NULL
function	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Nutr	NULL
.	NULL

,	NULL
6	NULL
:	NULL
527-563	NULL
,	NULL
1986	NULL
.	NULL

2	NULL
.	NULL

DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
The	NULL
vitamin	NULL
D	NULL
story	NULL
:	NULL
a	NULL
collaborative	NULL
effort	NULL
of	NULL
basic	NULL
science	NULL
and	NULL
clinical	NULL
medicine	NULL
.	NULL

FASEB	NULL
J.	NULL
,	NULL
2	NULL
:	NULL
224-236	NULL
,	NULL
1988	NULL
.	NULL

3	NULL
.	NULL

Stumpf	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Sar	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
/n	NULL
:	NULL
D.	NULL
V.	NULL
Cohn	NULL
,	NULL
R.	NULL
V.	NULL
Talmage	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Matthews	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Hormonal	NULL
Control	NULL
of	NULL
Calcium	NULL
Metabolism	NULL
,	NULL
pp	NULL
.	NULL

222-229	NULL
.	NULL

Amsterdam	NULL
:	NULL
Excerpta	NULL
Medica	NULL
,	NULL
1981	NULL
.	NULL

4	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Donaldson	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
and	NULL
Haussler	NULL
,	NULL
M.	NULL
R.	NULL
Dihydroxyvitamin	NULL
D	NULL
;	NULL
-induced	NULL
differentiation	NULL
in	NULL
a	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
:	NULL
receptor-mediated	NULL
maturation	NULL
to	NULL
macrophage-like	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
98	NULL
:	NULL
391-398	NULL
,	NULL
1984	NULL
.	NULL

5	NULL
.	NULL

Provvedini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Tsoukas	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
and	NULL
Deftos	NULL
,	NULL
L.	NULL
J.	NULL
Dihydroxyvitamin	NULL
D	NULL
;	NULL
receptors	NULL
in	NULL
human	NULL
leukocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
,	NULL
221	NULL
:	NULL
1181	NULL
,	NULL
1983	NULL
.	NULL

6	NULL
.	NULL

Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
Vitamin	NULL
D	NULL
:	NULL
myeloid	NULL
differentiation	NULL
and	NULL
proliferation	NULL
.	NULL

/n	NULL
:	NULL
R.	NULL
Neth	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Haematology	NULL
and	NULL
Blood	NULL
Transfusion	NULL
,	NULL
Vol	NULL
.	NULL

29.	NULL
pp	NULL
.	NULL

409-417	NULL
.	NULL

Berlin	NULL
:	NULL
Springer-Verlag	NULL
,	NULL
1985	NULL
.	NULL

7	NULL
.	NULL

Rigby	NULL
,	NULL
W.	NULL
F.	NULL
C.	NULL
,	NULL
Denome	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Fanger	NULL
,	NULL
M.	NULL
W.	NULL
Regulation	NULL
of	NULL
lymphokine	NULL
production	NULL
and	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
by	NULL
dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
79	NULL
:	NULL
1659-1664	NULL
,	NULL
1987	NULL
.	NULL

8	NULL
.	NULL

Tobler	NULL
,	NULL
A.	NULL
,	NULL
Gasson	NULL
,	NULL
J.	NULL
,	NULL
Reichel	NULL
,	NULL
H.	NULL
,	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
Granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
:	NULL
sensitive	NULL
and	NULL
receptor-mediated	NULL
regulation	NULL
by	NULL
dihydroxyvitamin	NULL
D	NULL
;	NULL
in	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
79	NULL
:	NULL
1700-1705	NULL
,	NULL
1987	NULL
.	NULL

9	NULL
.	NULL

Lemire	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Adams	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Sakai	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Jordan	NULL
,	NULL
S.	NULL
C.	NULL
1	NULL
Â«	NULL
,25-Dihydroxy-vitamin	NULL
D	NULL
;	NULL
suppresses	NULL
proliferation	NULL
and	NULL
immunoglobulin	NULL
production	NULL
by	NULL
normal	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
74	NULL
:	NULL
657-661	NULL
,	NULL
1984	NULL
.	NULL

10	NULL
.	NULL

Bar-Shavit	NULL
,	NULL
Z.	NULL
,	NULL
Teitelbaum	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Reitsma	NULL
,	NULL
P.	NULL
,	NULL
Hall	NULL
,	NULL
A.	NULL
,	NULL
Pegg	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Trial	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Kahn	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

Induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
and	NULL
bone	NULL
resorp-tion	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
:	NULL
5907-5911	NULL
,	NULL
1983	NULL
.	NULL

11	NULL
.	NULL

Miyaura	NULL
,	NULL
C.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
Kuribayashi	NULL
,	NULL
T.	NULL
,	NULL
Tanaka	NULL
,	NULL
H.	NULL
,	NULL
Konno	NULL
,	NULL
K.	NULL
,	NULL
Nishii	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
Dihydroxyvitamin	NULL
D	NULL
;	NULL
induces	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
leukocytes	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
102	NULL
:	NULL
937-943	NULL
,	NULL
1981	NULL
.	NULL

12	NULL
.	NULL

Dodd	NULL
,	NULL
R.	NULL
,	NULL
Cohen	NULL
,	NULL
M.	NULL
,	NULL
Newman	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Gray	NULL
,	NULL
T.	NULL
Vitamin	NULL
D	NULL
metabolites	NULL
change	NULL
the	NULL
phenotype	NULL
of	NULL
monoblastic	NULL
U937	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
:	NULL
7538-7541	NULL
,	NULL
1983	NULL
.	NULL

13	NULL
.	NULL

Nowell	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
and	NULL
Hungerford	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

A	NULL
minute	NULL
chromosome	NULL
in	NULL
human	NULL
chronic	NULL
granulocytic	NULL
leukemia	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
,	NULL
732	NULL
:	NULL
1497	NULL
,	NULL
1960	NULL
.	NULL

14	NULL
.	NULL

Dreazen	NULL
,	NULL
O.	NULL
,	NULL
Canaani	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Gale	NULL
,	NULL
R.	NULL
P.	NULL
Molecular	NULL
biology	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

Semin	NULL
.	NULL

Hematol	NULL
.	NULL

,	NULL
25	NULL
:	NULL
35-49	NULL
,	NULL
1988	NULL
.	NULL

15	NULL
.	NULL

Goto	NULL
,	NULL
T.	NULL
,	NULL
Nishiki	NULL
,	NULL
M.	NULL
,	NULL
Zaimen	NULL
,	NULL
A.	NULL
,	NULL
Bee	NULL
,	NULL
T.	NULL
,	NULL
Kempin	NULL
,	NULL
S.	NULL
,	NULL
Burchenal	NULL
,	NULL
J.	NULL
,	NULL
Strife	NULL
,	NULL
A.	NULL
,	NULL
Wisniewski	NULL
,	NULL
D.	NULL
,	NULL
Lambek	NULL
,	NULL
C.	NULL
,	NULL
Little	NULL
,	NULL
C.	NULL
,	NULL
Jhanwar	NULL
,	NULL
S.	NULL
,	NULL
Raju	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Clarkson	NULL
,	NULL
B	NULL
.	NULL

Growth	NULL
characteristics	NULL
of	NULL
leukemias	NULL
and	NULL
normal	NULL
hematopoietic	NULL
cells	NULL
in	NULL
Ph	NULL
'	NULL
+	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
and	NULL
effects	NULL
of	NULL
intensive	NULL
treatment	NULL
.	NULL

Blood	NULL
,	NULL
59	NULL
:	NULL
793-808	NULL
,	NULL
1982	NULL
.	NULL

16	NULL
.	NULL

Talpaz	NULL
,	NULL
M.	NULL
,	NULL
Kantarjian	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
McCredie	NULL
,	NULL
K.	NULL
,	NULL
Truijillo	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Keating	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Gutterman	NULL
,	NULL
J.	NULL
U.	NULL
Hematological	NULL
remission	NULL
and	NULL
cytogenitic	NULL
improvement	NULL
induced	NULL
by	NULL
recombinant	NULL
human	NULL
interferon	NULL
a	NULL
,	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
374	NULL
:	NULL
1065-1069	NULL
,	NULL
1986	NULL
.	NULL

17	NULL
.	NULL

Wiemann	NULL
,	NULL
M.	NULL
,	NULL
Hollmann	NULL
,	NULL
A.	NULL
,	NULL
Posner	NULL
,	NULL
M.	NULL
,	NULL
Arlin	NULL
,	NULL
Z.	NULL
,	NULL
Friedland	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Calabresi	NULL
,	NULL
P.	NULL
Establishment	NULL
of	NULL
a	NULL
new	NULL
Philadelphia	NULL
chromosome-positive	NULL
human	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
line	NULL
.	NULL

Clin	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
33	NULL
;	NULL
4602	NULL
,	NULL
1985	NULL
.	NULL

18	NULL
.	NULL

Huhn	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Posner	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Rayter	NULL
,	NULL
S.	NULL
I.	NULL
,	NULL
Foulkes	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
and	NULL
Frackelton	NULL
,	NULL
A.	NULL
R.	NULL
Cell	NULL
lines	NULL
and	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
derived	NULL
from	NULL
individuals	NULL
with	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
display	NULL
virtually	NULL
identical	NULL
proteins	NULL
phosphor-ylated	NULL
on	NULL
tyrosine	NULL
residues	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
:	NULL
4408-4412	NULL
,	NULL
1987	NULL
.	NULL

19	NULL
.	NULL

Posner	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Elboim	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
and	NULL
Santos	NULL
,	NULL
D.	NULL
The	NULL
construction	NULL
and	NULL
use	NULL
of	NULL
a	NULL
human-mouse	NULL
myeloma	NULL
analogue	NULL
suitable	NULL
for	NULL
the	NULL
routine	NULL
production	NULL
of	NULL
hybridomas	NULL
secreting	NULL
human	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

Hybridoma	NULL
,	NULL
6	NULL
:	NULL
611-625	NULL
,	NULL
1987	NULL
.	NULL

20	NULL
.	NULL

Eil	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Marx	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Nuclear	NULL
uptake	NULL
of	NULL
1,25-dihydroxy	NULL
[	NULL
'Hcholecalciferol	NULL
in	NULL
dispersed	NULL
fibroblasts	NULL
cultured	NULL
from	NULL
normal	NULL
human	NULL
skin	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
78	NULL
:	NULL
2562-2566	NULL
,	NULL
1981	NULL
.	NULL

21	NULL
.	NULL

Scatchard	NULL
,	NULL
G.	NULL
The	NULL
attraction	NULL
of	NULL
proteins	NULL
for	NULL
small	NULL
molecules	NULL
and	NULL
ions	NULL
.	NULL

Ann	NULL
.	NULL

NY	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
51	NULL
:	NULL
660-672	NULL
,	NULL
1949	NULL
.	NULL

3093	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

1a,25-DIHYDROXYVITAMIN	NULL
D	NULL
;	NULL
EFFECTS	NULL
ON	NULL
CML	NULL
CELLS	NULL
Liberman	NULL
,	NULL
U	NULL
.	NULL

A.	NULL
,	NULL
Eil	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Marx	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Resistance	NULL
to	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
:	NULL
association	NULL
with	NULL
heterogeneous	NULL
defects	NULL
in	NULL
cultured	NULL
skin	NULL
fibroblasts	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
77	NULL
:	NULL
192-200	NULL
,	NULL
1979	NULL
.	NULL

Gamblin	NULL
,	NULL
G.	NULL
T.	NULL
,	NULL
Liberman	NULL
,	NULL
U	NULL
.	NULL

A.	NULL
,	NULL
Eil	NULL
,	NULL
C.	NULL
,	NULL
Downs	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
Jr.	NULL
,	NULL
DeGrange	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
Marx	NULL
,	NULL
S.	NULL
J.	NULL
Vitamin	NULL
D-dependent	NULL
ricketts	NULL
type	NULL
II	NULL
:	NULL
correlation	NULL
between	NULL
clinical	NULL
features	NULL
and	NULL
defects	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
-induced	NULL
25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
-24-hydroxylase	NULL
in	NULL
skin	NULL
fibroblasts	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
75	NULL
:	NULL
954-960	NULL
,	NULL
1985	NULL
.	NULL

Samuel	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
and	NULL
Jocklik	NULL
,	NULL
W.	NULL
K.	NULL
A	NULL
protein	NULL
synthesizing	NULL
system	NULL
from	NULL
interferon-treated	NULL
cells	NULL
that	NULL
discriminates	NULL
between	NULL
cellular	NULL
and	NULL
viral	NULL
messenger	NULL
RNAs	NULL
.	NULL

Virology	NULL
,	NULL
58	NULL
:	NULL
476-491	NULL
,	NULL
1974	NULL
.	NULL

Chirgwin	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Przybyla	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
MacDonald	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Rutter	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

Isolation	NULL
of	NULL
biologically	NULL
active	NULL
ribonucleic	NULL
acid	NULL
from	NULL
sources	NULL
enriched	NULL
in	NULL
ribonuclease	NULL
.	NULL

Biochemistry	NULL
,	NULL
18	NULL
:	NULL
5294-5299	NULL
,	NULL
1975	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Sambrook	NULL
,	NULL
J.	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
:	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
1982	NULL
.	NULL

Guo	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
and	NULL
Wu	NULL
,	NULL
R.	NULL
Exonuclease	NULL
III	NULL
:	NULL
use	NULL
for	NULL
DNA	NULL
sequence	NULL
analysis	NULL
and	NULL
in	NULL
specific	NULL
deletions	NULL
of	NULL
nucleotides	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
700	NULL
:	NULL
60-96	NULL
,	NULL
1983	NULL
.	NULL

Sadhu	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Gedamu	NULL
,	NULL
L.	NULL
A	NULL
procedure	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
RNA-free	NULL
plasmid	NULL
DNA	NULL
.	NULL

Biotechniques	NULL
,	NULL
6	NULL
:	NULL
20-21	NULL
,	NULL
1988	NULL
.	NULL

Feinberg	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
and	NULL
Vogelstein	NULL
,	NULL
B	NULL
.	NULL

A	NULL
technique	NULL
for	NULL
radiolabeling	NULL
DNA	NULL
restriction	NULL
endonuclease	NULL
fragments	NULL
to	NULL
high	NULL
specific	NULL
activity	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
137	NULL
:	NULL
266-267	NULL
,	NULL
1983	NULL
.	NULL

Lozzio	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
Lozzio	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
and	NULL
Machado	NULL
,	NULL
E.	NULL
Human	NULL
myelogenous	NULL
(	NULL
Ph'+	NULL
)	NULL
leukemia	NULL
cell	NULL
line	NULL
:	NULL
transplantation	NULL
into	NULL
athymic	NULL
mice	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
56	NULL
:	NULL
627-629	NULL
,	NULL
1976	NULL
.	NULL

Machado	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Lozzio	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
Lozzio	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Lair	NULL
,	NULL
S.	NULL
V.	NULL
,	NULL
and	NULL
Aggio	NULL
,	NULL
M.	NULL
C.	NULL
Development	NULL
of	NULL
myelosarcomas	NULL
from	NULL
human	NULL
myelogenous	NULL
leukemia	NULL
cells	NULL
transplanted	NULL
in	NULL
athymic	NULL
mice	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
37	NULL
:	NULL
3995-4002	NULL
,	NULL
1977	NULL
.	NULL

Foon	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Todd	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
III	NULL
.	NULL

Immunological	NULL
classification	NULL
of	NULL
leukemia	NULL
and	NULL
lymphoma	NULL
.	NULL

Blood	NULL
,	NULL
68	NULL
:	NULL
1-31	NULL
,	NULL
1986	NULL
.	NULL

Todd	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Liu	NULL
,	NULL
D.	NULL
Y.	NULL
Mononuclear	NULL
phagocytic	NULL
activation	NULL
:	NULL
activation	NULL
associated	NULL
antigens	NULL
.	NULL

Fed	NULL
.	NULL

Proc	NULL
.	NULL

,	NULL
45	NULL
:	NULL
2829-2836	NULL
,	NULL
1986	NULL
.	NULL

Todd	NULL
,	NULL
R.	NULL
,	NULL
Roach	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Arnaout	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

The	NULL
modulated	NULL
expression	NULL
of	NULL
MoS	NULL
,	NULL
a	NULL
human	NULL
myelomonocyte	NULL
plasma	NULL
marker	NULL
antigen	NULL
.	NULL

Blood	NULL
,	NULL
65	NULL
:	NULL
964-973	NULL
,	NULL
1985	NULL
.	NULL

Zuckerman	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Surprenant	NULL
,	NULL
Y.	NULL
M.	NULL
,	NULL
and	NULL
Tang	NULL
,	NULL
J.	NULL
Synergistic	NULL
effect	NULL
of	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
and	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
on	NULL
the	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
U937	NULL
.	NULL

Blood	NULL
,	NULL
71	NULL
:	NULL
619-624	NULL
,	NULL
1988	NULL
.	NULL

Tanaka	NULL
,	NULL
H.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
Miyaura	NULL
,	NULL
C.	NULL
,	NULL
Kuribayashi	NULL
,	NULL
T.	NULL
,	NULL
Konno	NULL
,	NULL
Nishii	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
1a,25-Dihydroxycholecalciferol	NULL
and	NULL
a	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
204	NULL
:	NULL
713-719	NULL
,	NULL
1982	NULL
.	NULL

Kuribayashi	NULL
,	NULL
T.	NULL
,	NULL
Tanaka	NULL
,	NULL
H.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
Functional	NULL
defect	NULL
of	NULL
38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

3094	NULL
variant	NULL
clones	NULL
of	NULL
a	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
resistant	NULL
to	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

Endocrinology	NULL
,	NULL
773	NULL
:	NULL
1992-1998	NULL
,	NULL
1983	NULL
.	NULL

Wiemann	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Khorsand	NULL
,	NULL
J.	NULL
,	NULL
Poisson	NULL
,	NULL
L.	NULL
,	NULL
Frackeiton	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
and	NULL
Calabresi	NULL
,	NULL
P.	NULL
Evaluation	NULL
of	NULL
differentiation-inducing	NULL
drugs	NULL
against	NULL
human	NULL
chronic	NULL
myelogenous	NULL
leukemic	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Proc	NULL
.	NULL

Am	NULL
.	NULL

Assoc	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
29	NULL
:	NULL
495	NULL
,	NULL
1988	NULL
.	NULL

Castagna	NULL
,	NULL
M.	NULL
,	NULL
Takai	NULL
,	NULL
Y.	NULL
,	NULL
Kaibuchi	NULL
,	NULL
K.	NULL
,	NULL
Sano	NULL
,	NULL
K.	NULL
,	NULL
Kikkawa	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

Direct	NULL
activation	NULL
of	NULL
calcium-activated	NULL
,	NULL
phospholipid-dependent	NULL
protein	NULL
kinase	NULL
by	NULL
tumor-promoting	NULL
phorbol	NULL
esters	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
257	NULL
:	NULL
7847-7851	NULL
,	NULL
1982	NULL
.	NULL

Kuroki	NULL
,	NULL
T.	NULL
,	NULL
Chida	NULL
,	NULL
K.	NULL
,	NULL
Hashiba	NULL
,	NULL
H.	NULL
,	NULL
Hosoi	NULL
,	NULL
J.	NULL
,	NULL
Hosimi	NULL
,	NULL
J.	NULL
,	NULL
Sasaki	NULL
,	NULL
K.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Suda	NULL
,	NULL
T.	NULL
Regulation	NULL
of	NULL
cell	NULL
differentiation	NULL
and	NULL
tumor	NULL
promotion	NULL
by	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

Carcinogenesis	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
10	NULL
:	NULL
275-286	NULL
,	NULL
1985	NULL
.	NULL

Ways	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
Dodd	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Bennett	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
Gray	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
and	NULL
Earp	NULL
,	NULL
H.	NULL
S.	NULL
Dihydroxyvitamin	NULL
D	NULL
,	NULL
enhances	NULL
phorbol	NULL
ester-stimulated	NULL
differentiation	NULL
and	NULL
protein	NULL
kinase	NULL
C-dependent	NULL
substrate	NULL
phosphorylation	NULL
activity	NULL
in	NULL
the	NULL
U937	NULL
human	NULL
monoblastoid	NULL
cell	NULL
.	NULL

Endocrinology	NULL
,	NULL
727	NULL
:	NULL
1654-1661	NULL
,	NULL
1987	NULL
.	NULL

Canaani	NULL
,	NULL
E.	NULL
,	NULL
Steiner-Saltz	NULL
,	NULL
D.	NULL
,	NULL
Aghai	NULL
,	NULL
E.	NULL
,	NULL
Bale	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Berrebi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Januszewicz	NULL
,	NULL
E.	NULL
Altered	NULL
transcription	NULL
of	NULL
an	NULL
oncogene	NULL
in	NULL
chronic	NULL
myeloid	NULL
leukaemia	NULL
.	NULL

Lancet	NULL
,	NULL
7	NULL
:	NULL
593-595	NULL
,	NULL
1984	NULL
.	NULL

Konopka	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Watanabe	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Witte	NULL
,	NULL
O.	NULL
N.	NULL
An	NULL
alteration	NULL
of	NULL
the	NULL
human	NULL
c-ab/	NULL
protein	NULL
in	NULL
K562	NULL
leukemia	NULL
cells	NULL
unmasks	NULL
associated	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
.	NULL

Cell	NULL
,	NULL
37	NULL
;	NULL
1035-1042	NULL
,	NULL
1984	NULL
.	NULL

Ben-Meriah	NULL
,	NULL
Y.	NULL
,	NULL
Daleu	NULL
,	NULL
G.	NULL
Q.	NULL
,	NULL
Mes-Masson	NULL
,	NULL
A-M.	NULL
,	NULL
Witte	NULL
,	NULL
O.	NULL
N.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
The	NULL
chronic	NULL
myelogenous	NULL
leukemia-specific	NULL
P210	NULL
protein	NULL
is	NULL
the	NULL
product	NULL
of	NULL
the	NULL
ber/ab/	NULL
hybrid	NULL
gene	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
,	NULL
233	NULL
:	NULL
212-214	NULL
,	NULL
1986	NULL
.	NULL

Simpson	NULL
,	NULL
R.	NULL
U.	NULL
,	NULL
Hsu	NULL
,	NULL
T.	NULL
,	NULL
Begley	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Mitchell	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
and	NULL
Alizadeb	NULL
,	NULL
B.	NULL
N.	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
c-myc	NULL
proto-oncogene	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
in	NULL
HL-60	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
262	NULL
:	NULL
4104-4108	NULL
,	NULL
1987	NULL
.	NULL

Lachman	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
and	NULL
Skoultchi	NULL
,	NULL
A.	NULL
I	NULL
.	NULL

Expression	NULL
of	NULL
c-myc	NULL
changes	NULL
during	NULL
differentiation	NULL
of	NULL
mouse	NULL
erythroleukaemia	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
370	NULL
:	NULL
592-594	NULL
,	NULL
1984	NULL
.	NULL

Kelly	NULL
,	NULL
K.	NULL
,	NULL
Cochran	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Stiles	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
and	NULL
Leder	NULL
,	NULL
P.	NULL
Cell-specific	NULL
regulation	NULL
of	NULL
c-myc	NULL
gene	NULL
by	NULL
lymphocyte	NULL
mitogens	NULL
and	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
.	NULL

Cell	NULL
,	NULL
35	NULL
:	NULL
603-610	NULL
,	NULL
1983	NULL
.	NULL

Reitsma	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Rothberg	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Astrin	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Trial	NULL
,	NULL
J.	NULL
,	NULL
Bar-Shavit	NULL
,	NULL
Z.	NULL
,	NULL
Hall	NULL
,	NULL
A.	NULL
,	NULL
Teitelbaum	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Kahn	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

Regulation	NULL
of	NULL
myc	NULL
gene	NULL
expression	NULL
in	NULL
HL-60	NULL
leukemia	NULL
cells	NULL
by	NULL
a	NULL
vitamin	NULL
D	NULL
metabolite	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
306	NULL
:	NULL
492-494	NULL
,	NULL
1983	NULL
.	NULL

Testa	NULL
,	NULL
U.	NULL
,	NULL
Ferbus	NULL
,	NULL
D.	NULL
,	NULL
Gabbianelli	NULL
,	NULL
M.	NULL
,	NULL
Pascucci	NULL
,	NULL
B.	NULL
,	NULL
Boccoli	NULL
,	NULL
G.	NULL
,	NULL
Louache	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Thang	NULL
,	NULL
M.	NULL
N.	NULL
Effect	NULL
of	NULL
endogenous	NULL
and	NULL
exogenous	NULL
interferons	NULL
on	NULL
the	NULL
differentiation	NULL
of	NULL
human	NULL
monocyte	NULL
cell	NULL
line	NULL
U937	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
48	NULL
:	NULL
82-88	NULL
,	NULL
1988	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Effects	NULL
of	NULL
1Â¢,25-Dihydroxyvitamin	NULL
Ds	NULL
on	NULL
the	NULL
Human	NULL
Chronic	NULL
Myelogenous	NULL
Leukemia	NULL
Cell	NULL
Line	NULL
RWLeu-4	NULL
Stephen	NULL
R.	NULL
Lasky	NULL
,	NULL
William	NULL
Bell	NULL
,	NULL
Richard	NULL
D.	NULL
Huhn	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1990	NULL
;	NULL
50:3087-3094	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/50/10/3087	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/50/10/3087	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Â©	NULL
1990	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

